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ABSTRACT 
Prostaglandin E2 (PGE2) is an inflammatory and oncogenic lipid mediator. It is mainly formed 
via metabolism of arachidonic acid by cyclooxygenases (COX-1 and COX-2) and the terminal 
enzyme microsomal prostaglandin E synthase-1 (mPGES-1). Widely used non-steroidal anti-
inflammatory drugs (NSAIDs) inhibit COX-1 and/or COX-2, resulting in decreased PGE2 
production and reduced inflammation. However, NSAIDs block the production of many other 
lipid mediators that have important physiological and resolving actions, and these drugs cause 
gastrointestinal bleeding and/or increase the risk for severe cardiovascular events. Selective 
inhibition of downstream mPGES-1 for reduction in only PGE2 biosynthesis is therefore an 
anticipated therapeutic strategy. This PhD thesis aims to increase knowledge on mPGES-1 and 
its inhibition in inflammation and cancer. 
Cultures of human cells, preclinical animal models, and clinical material from humans were 
used to study inflammation at the molecular level, specifically after manipulation of 
prostaglandin production. The main method of analysis was liquid chromatography tandem 
mass spectrometry (LC-MS/MS). 
This thesis showed that prostacyclin and PGE2 are potentially important mediators in human 
tendon disease (Paper I). Proteomics and lipidomics data suggested differences in cellular 
protein and lipid profiles upon pharmacological inhibition of mPGES-1 or COX-2 in cancer 
cells, where inhibition of mPGES-1 potentiated the cytotoxicity of cytostatic drugs in vitro 
(Paper II). Daily treatment with an mPGES-1 inhibitor suppressed neuroblastoma tumor 
growth in vivo via decreased angiogenesis, reduced infiltration of cancer-associated fibroblasts, 
and a shift towards anti-cancer macrophage polarization (Paper III). Lastly, characterization 
of five new mPGES-1 inhibitors in preclinical models showed decreased swelling in a paw 
edema assay in rats and reduced norepinephrine-induced vasoconstriction in human arteries ex 
vivo (Paper IV). 
In summary, results from this PhD thesis increase knowledge of prostaglandins in pathology 
and expand the principle of mPGES-1 as a viable target to treat inflammation and cancer. 
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1 INTRODUCTION 
1.1 INFLAMMATION AND CANCER 
Inflammation is a highly controlled immune response to eliminate the cause of tissue injury or 
infection and to initiate tissue repair back to homeostasis via resolution (1, 2). However, 
inflammation is not always terminated. Unresolved inflammation causes persistent pain, tissue 
degeneration, and loss of function. Inflammatory responses drive many autoimmune diseases 
(3) and inflammation is a hallmark of cancer (4). There is a great need for drugs that are anti-
inflammatory and safe. 
Inflammatory processes are divided into acute or chronic. The acute phase includes the rapid 
influx of neutrophils and monocytes to remove pathogens and damaged cells via phagocytosis. 
This response subsides within days. The innate reactions trigger the activation of the adaptive 
responses, which means education and recruitment of lymphocytes that neutralize pathogens 
or kill dysfunctional cells. If the adaptive responses fail, the inflammation becomes chronic. It 
is not fully understood how this occurs, but the chronic inflammatory state is characterized by 
presence of pro-inflammatory components and lack of resolving mechanisms. Inflammatory 
responses are present in many diseases including rheumatic diseases, multiple forms of cancer, 
neurodegenerative diseases, and cardiovascular diseases.  
The complex signaling at the site of inflammation involves several distinct cell types and 
molecules. This complexity does also change throughout the course of inflammation (and 
resolution). Of particular interest are potent bioactive lipids of the prostanoid family, especially 
prostaglandin E2 (PGE2). PGE2 is a central mediator of pain, edema, and cartilage erosion 
typically observed in the joints of rheumatoid arthritis patients (5, 6). At the same time, PGE2 
is a promotor of the immunosuppressive tumor microenvironment with major impact on tumor 
progression (4, 7, 8). Multiple non-steroidal anti-inflammatory drugs (NSAIDs) exist in clinical 
practice that unselectively decrease PGE2 production, but these drugs are all associated with 
severe adverse effects. Selective inhibition of PGE2 production with small molecule inhibitors 
is therefore a highly anticipated therapeutic strategy in inflammation and cancer. This is the 
topic of this thesis. 
1.2 PROSTANOID METABOLISM 
Prostanoids belong to the lipid class eicosanoids, which comprises all lipid metabolites 
produced from polyunsaturated fatty acids (PUFA) with 20 carbon in chain length. The 
eicosanoid family therefore comprises a diverse population of bioactive lipids including 
prostanoids, hydroxyeicosatetraenoic acids (HETEs), leukotrienes (LTs), eoxins (EXs), and 
resolvins (Rvs). Eicosanoid research traces back to the 1930s when Ulf von Euler first coined 
the name “prostaglandin” for an unknown substance in seminal fluid. Sune Bergström and 
Bengt Samuelsson later characterized this molecule and many more prostaglandins, for which 
they together with Sir John Vane were awarded the Nobel Prize in Physiology or Medicine in 
1982. Ever since, increasing amount of research have demonstrated that many different types 
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of cells produce eicosanoids and these mediators have numerous important physiological and 
pathological roles. 
The first reaction in the biosynthesis of prostanoids (Figure 1) is the release of arachidonic 
acid (AA) from the phospholipid cell membrane. This is catalyzed by phospholipases, in 
particular cytosolic phospholipase A2 (cPLA2), which is activated and translocated to the cell 
membrane upon phosphorylation and increased Ca2+ concentration. This enzyme specifically 
cleaves fatty acids from position two (sn-2) of phospholipids. The next step is catalyzed by the 
cyclooxygenases (COX-1 and COX-2). These enzymes convert AA to unstable PGH2 via 
PGG2. This occurs by abstraction of a hydrogen on carbon no. 13 followed by lipid 
peroxidation on carbon no. 11 and carbon no. 15. The peroxide group on carbon no. 11 binds 
with carbon no. 9 and the peroxide group on carbon no. 15 is reduced to a hydroxyl group, 
yielding PGH2 (9). The lower case “2” stands for the number of double bonds in the acyl chain. 
The final step in the biosynthesis is the conversion of PGH2 by terminal synthases into the main 
prostanoids: PGE2, PGD2, PGF2, prostacyclin (PGI2), and thromboxane A2 (TXA2) (10). PGE2 
is generated by cytosolic PGE synthase (cPGES), microsomal PGE synthase (mPGES)-1, and 
mPGES-2. PGD2 is generated by hematopoietic PGD synthase (H-PGDS) and lipocalin-type 
PGD synthase (L-PGDS). PGF2α is generated by PGH2 9,11-endoperoxide reductase and PGE2 
9-keto reductase (collectively named PGF synthase, PGFS). Prostacyclin is generated by 
prostacyclin synthase (PGIS). Finally, TXA2 is generated by TX synthase (TXAS). The 
terminal enzymes display a preferential, but not exclusive, coupling to the respective COX 
enzymes. COX-1 couples to cPGES, PGFS, and TXAS, while COX-2 couples to mPGES-1, 
mPGES-2, and PGIS (11). In addition, PGH2 can be generated by one cell and further 
metabolized by neighboring cells (transcellular biosynthesis) (12). 
Synthesized prostanoids are secreted from cells via passive diffusion or multidrug resistance 
protein-4 (MRP4) (13). Once released from cells, prostanoids signal through distinct G-protein 
coupled receptors in autocrine or paracrine fashion (14), presented in Figure 2. The 
endogenous concentration is dependent on the activity of cPLA2, the expression of COX, and 
the expression of terminal synthases, which vary depending on cell type and cell state. The 
estimated affinities of prostanoids to the prostanoid receptors are in the nanomolar range (0.3-
25 nM) (15). Prostanoids are fast acting and short-lived, as they are taken up by cells via 
prostaglandin transporter (PGT) and primarily oxidized by 15-hydroxyprostaglandin 
dehydrogenase (15-PGDH) to generate inactive forms. Prostacyclin and TXA2 are unstable at 
physiological and aqueous conditions and are non-enzymatically hydrolyzed into 6-keto PGF1α 
and TXB2, respectively. Prostanoid metabolites are then excreted into the blood stream and 
filtered out in the kidneys. In summary, the identity and concentration of prostanoids are cell 
and tissue specific, which is evident by the complex set-up of expression for the enzymes 
implicated in prostanoid catabolism and anabolism. 
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Figure 1. Prostanoid biosynthesis. The COX enzymes convert AA into PGH2 that is further 
metabolized by the terminal synthases into the main prostanoids. Prostacyclin (PGI2) and TXA2 are 
rapidly converted into inactive metabolites 6-keto PGF1α and TXB2, respectively. PGF2α can be 
generated from PGH2 or PGE2. Highlighted in black is the inducible terminal synthase mPGES-1. 
 
 
 
Figure 2. Prostanoid signaling. Each of the five prostanoid receptors (EP, DP, FP, IP, and TP) display 
a preference for one of the main prostanoids; however, all prostanoids display binding to all receptors 
with varying affinities. The figure shows the overall classification based on the main effect on smooth 
muscle cells (relaxant/contractile) or action on cAMP production (stimulatory/inhibitory). Signaling 
via EP3 and DP1 can promote calcium release, depending on receptor isoform. 
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1.3 PROSTANOID FUNCTIONS IN HEALTH AND DISEASE 
Many types of cells produce prostanoids that can act on even more types of cells. This section 
will present each of the five main prostanoids separately in terms of their role in physiology, 
inflammation, and cancer. The molecular structures of prostanoids are presented in Figure 3. 
PGE2 
PGE2 is a regulator of blood pressure (16) and blood flow (17), a protector of mucosal integrity 
in the gastrointestinal tract (18), a component in renal homeostasis (19), an essential bioactive 
lipid in female fertility (20), and a mediator of wakefulness (21). As for pathophysiology, PGE2 
is involved in all processes leading to the signs of acute inflammation, i.e. heat, redness, 
swelling, and pain, (8). These features are driven by PGE2 (and also prostacyclin and LTB4), 
causing neutrophil and macrophage infiltration via vasodilation and enhanced vascular 
permeability (22). The initial burst in PGE2 production is essential for the resolution of 
inflammation, as PGE2 turns on transcription of enzymes implicated in the generation of pro-
resolving lipid mediators (23). Additionally, PGE2 can act on a wide variety of immune cells 
to modulate immune responses associated with chronic inflammation and cancer. PGE2 
promotes tumor-favoring M2 polarization of tumor-associated macrophages (TAMs), attracts 
immunosuppressive myeloid-derived suppressor cells (MDSCs), enhances the immunity 
inhibitory function of regulatory T cells (Tregs), decreases amount and maturation of 
infiltrating antigen-presenting dendritic cells, inhibits anti-tumor activity of natural killer (NK) 
cells and cytotoxic T cells, and promotes inflammatory functions of T helper (Th) 17 cells (7, 
24, 25). 
PGE2 signals through four receptors named EP1-4. EP1 is Gq coupled, where binding 
ultimately results in increase in intracellular Ca2+ concentration and activation of protein kinase 
C (PKC). EP2 signaling is Gs coupled, resulting in activation of adenylyl cyclase (AC), 
production of cAMP, and activation of protein kinase A (PKA). EP3 is classified as Gi coupled 
(but may signal via Gq depending on EP3 isoform), resulting in inactivation of PKA by 
reduction in cAMP production via inhibition of AC. EP4 is coupled to Gs that results in 
increased cAMP concentration by activation of AC (like EP2). Signaling via EP4 also activates 
phosphoinositide 3-kinase (PI3K). EP signaling will ultimately influence activation and 
translocation of transcription factors, including cAMP response element-binding protein 
(CREB) (26), protein kinase B (AKT) (27), extracellular signal-regulated kinases (ERK) (28), 
and p38 mitogen-activated protein kinases (MAPK) (29). This translate into PGE2 having the 
ability to influence survival, proliferation, and migration of cells (30, 31). 
Mouse lacking any of the EP receptors have distinct phenotypes (32). For example, deletion of 
EP1 results in decreased PGE2-induced tactile pain response (allodynia) (33). EP2 knockout 
mice are less fertile (34), sensitive to salt-induced hypertension (34), and show no 
bronchodilation in response to PGE2 (35). Deletion of EP3 leads to impaired febrile response 
to interleukin-1β (IL-1β) or lipopolysaccharide (LPS) (36), reduced acetic acid-induced 
writhing after LPS treatment (37), and worse allergic response to ovalbumin-induced asthma 
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(38). Mice deficient in EP4 display reduced ear swelling in a model of contact hypersensitivity 
(39) and develop more severe colitis induced by dextran sulfate sodium (DSS) (40). 
The COX/mPGES-1/PGE2 pathway is induced in several forms of cancer (41-48). The 
increased expression of COX-2 and mPGES-1 is linked to decreased survival rate in cancer 
(49, 50). Not only is the biosynthesis of PGE2 important but also the secretion, the uptake, and 
the hydrolysis of PGE2 are collectively determining the active concentration in the tumor 
microenvironment (51). A pro-tumorigenic role has been demonstrated for PGE2 in multiple 
studies, either by injection of PGE2, use of EP antagonist, or pharmacological inhibition or 
genetic deletion of COX or mPGES-1 (reviewed in (25)). This will be discussed at a later stage, 
but a recent publication nicely concluded the significance of PGE2 in cancer. Zelenay et al. 
reported that tumor COX activity, namely PGE2 production, promoted immunosuppression in 
xenograft models of breast (BrafV600E and 4T1) and colon (CT26) cancer, and that COX 
deficiency in the cancer cells induced a less immunosuppressive microenvironment (52). The 
authors showed that inhibition of COX by NSAIDs (aspirin or celecoxib) had no effect alone 
on tumor growth in immunocompetent mice but the inhibitors enhanced the effect of 
immunotherapy (anti-PD1 antibody). 
Increasing amount of literature has identified the COX/mPGES-1/PGE2 pathway in other 
inflammatory diseases. This includes rheumatic diseases such as rheumatoid arthritis (53), 
osteoarthritis (54, 55), and idiopathic inflammatory myopathies (56) along with neurological 
diseases such as Alzheimer’s disease (57) and multiple sclerosis (58), and cardiovascular 
diseases such as atherosclerosis (59, 60), aortic aneurysm (61), and ischemic stroke (62). 
In summary, PGE2 is an important mediator of many inflammatory and immunoregulatory 
processes in multiple diseases. 
PGD2  
PGD2 and PGE2 are isomers. They differ in the functional groups of carbon no. 9 (hydroxyl 
group for PGD2, ketone group for PGE2) and carbon no. 11 (ketone group for PGD2, hydroxyl 
group for PGE2). PGD2 signals through DP1 (Gs coupled) and DP2 (Gi coupled), which affects 
cAMP production. This prostanoid is recognized for regulating sleep (63) and reproduction 
functions (64). PGD2 is the main product of mast cells in allergic responses and it is found 
elevated in bronchoalveolar lavage fluid in patients with severe asthma (65), where it causes 
bronchoconstriction and vasodilation, increases mucous production, and enables influx of 
immune cells by increasing capillary permeability (66). PGD2 can also bind TP receptor, 
causing smooth muscle constriction and platelet aggregation, which contributes to the effects 
seen in asthma. 
Eguchi et al. reported that mice lacking L-PGDS were insensitive to PGE2- or bicuculline-
induced allodynia but the mice responded normally to thermal hyperalgesia (increased 
sensitivity to pain, in this case heat) (67). Allodynia was restored with injections of PGD2 in 
the KO mice, highlighting a role a PGD2 in neuropathic pain. Rajakariar et al. showed that 
mice lacking H-PGDS displayed a more severe acute phase of inflammation and impairment 
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of resolution in a model of peritonitis (68). They demonstrated that absence of PGD2 production 
coincide with decreased concentration of IL-10, increased concentration of tumor necrosis 
factor-α (TNF-α), and increased concentration of monocyte chemoattractant protein-1 in the 
exudates. This resulted in elevated levels of polymorphonuclear cells (PMN) in the acute phase 
with decreased draining of macrophages from the peritoneum to the lymph nodes in the late 
phase. Moreover, PGD2 is metabolized to 15-deoxy-Δ12,14-PGJ2 (15d-PGJ2) that can modulate 
inflammatory responses via peroxisome proliferator-activated receptor gamma (PPARγ) (69). 
Injection of 15d-PGJ2 in the peritonitis study described above reversed the lack of resolution 
caused by deletion of H-PGDS (68). 15d-PGJ2 and other cyclopentenone PGs can act anti-viral 
in vitro and in vivo through inhibition of viral protein synthesis via induced synthesis of heat-
shock proteins (70). 
The immunomodulatory effects of PGD2 have implications in cancer. PGD2 signaling  
decreased the cytotoxic activity of NK cells in vitro (71). However, treatment with PGD2 or L-
PGDS decreased proliferation rate of multiple gastric cancer cell lines and tumor growth in a 
xenograft mice model of gastric cancer (72). In addition, treatment with 15d-PGJ2 induced cell 
death of cancer cells in vitro (73-77) and decreased tumor growth in vivo (78). Genetic deletion 
of H-PGDS increased while overexpression of H-PGDS decreased intestinal tumorigenesis in 
ApcMin/+ mice (79), again highlighting anti-cancer properties of PGD2. This translates into that 
PGD2 has immunosuppressive effects and at the same time anti-cancer properties, for example 
via suppression of tumor angiogenesis (80). 
These studies conclude that PGD2 is a mediator of both inflammation and resolution with 
implications in tumor progression. 
PGF2α  
PGF2α is an important mediator in childbirth and a regulator of blood pressure. It is also 
implicated in inflammation and cancer (8). This prostanoid signals through the FP receptor, 
which exist in the two isoforms FPA and FPB. The FP receptor is Gq coupled (like EP1), where 
signaling increases intracellular Ca2+ and activation of PKC. In addition, FP signaling can 
activate Rho pathway via Gq-independent mechanism that regulate intracellular actin dynamics 
(81). PGF2α has hydroxyl groups on both carbon no. 9 and carbon no. 11, making it very similar 
in structure to PGE2 and PGD2. Both PGE2 and PGD2 can bind to the FP receptor, but with 
lower affinities (15). PGF2α affects blood pressure via the salt balance in the kidneys and via 
direct vasoconstriction of vascular smooth muscle cells (82). 
Genetic deletion of the FP receptor is reported protective in some mice models where it 
decreases LPS-induced tachycardia (increased heart rate) (83), limits pulmonary fibrosis post-
microbial invasion (84), and reduces hyperlipidemia-induced atherosclerosis (85). Basu et al. 
reported that both PGF2α metabolite 15-keto-dihydro-PGF2α and oxidative stress marker 8-iso-
PGF2α are increased in plasma in a model of septic shock in pigs (86). They have also showed 
that elevated levels of 15-keto-dihydro-PGF2α correlated with elevated levels of 8-iso-PGF2α in 
serum and synovial fluid from patients with arthritis, including rheumatoid arthritis (87). The 
group of Henry N. Jabbour has studied PGF2α in cancer. PGF2α can stimulate migration and 
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invasion of colon (88) and endometrial (89) cancer cells in vitro. In addition, PGF2α can induce 
proliferation (90) and increase secretion of vascular endothelial growth factor (VEGF) (91) in 
endometrial cancer cell lines. The same group has showed that stable expression of the FP 
receptor on endometrial cancer cells in a xenograft model increased neutrophil infiltration, but 
this did not influence tumor growth (92). 
Prostacyclin 
Prostacyclin is a regulator of vascular homeostasis and a mediator of edema and pain. It is 
mainly produced by endothelial and smooth muscle cells, where upon it functions as a 
vasodilator and inhibitor of platelet aggregation (94). The vasodilative effect of prostacyclin is 
evident in pulmonary atrial hypertension and Renaud’s phenomenon (episodes of reduced 
blood flow in fingers and toes), where infusion of prostacyclin analogues are used as treatments 
(95, 96). Prostacyclin signals through the IP receptor that is Gs coupled. Moreover, prostacyclin 
is reported as the main prostaglandin found in synovial fluid of patients with rheumatoid 
arthritis (97). Honda et al. demonstrated that mice lacking the IP receptor had reduced disease 
score in the collagen-induced arthritis (CIA) model, and that IP deletion did not affect the 
production of autoantibodies. (98). Chen et al. showed reduced arthritis score after IP deletion 
in the K/BxN serum-transfer arthritis model in mice (99). 
Work by Murata et al. demonstrated that mice lacking the IP receptor had decreased paw 
edema, reduced pain sensation when challenged with carrageenan, and smaller number of 
writhing responses in the acetic-induced writhing model (100). However, the mice displayed 
increased tendencies towards thrombosis. The same group later showed that both IP and EP3 
receptor signaling mediate pain following pre-treatment with LPS in the acetic-induced 
writhing model (37). Moreover, IP receptor antagonists relieve pain in multiple pain models 
(101, 102). Sasaki et al. showed that genetic deletion of PGIS in mice leads to suppressed 
inflammatory reactions (thioglycollate-induced peritonitis and acetic acid-induced writhing) 
but accelerates azoxymethane (AOM)-induced colon carcinogenesis (103). Treatment with 
prostacyclin analog iloprost resulted in accumulation of macrophages in the tumor tissue and 
decreased tumor formation in the lungs, and this effect was equally great in mice lacking the 
IP receptor (104). This suggests that the anti-cancer effect from iloprost was not mediated via 
IP receptor signaling. The authors showed that iloprost increased PPARγ activity in A549 lung 
cancer cells and epithelial H661 cells. The protective effect of prostacyclin signaling in cancer 
is also suggested to be mediated via PPARβ/δ (105), but the literature is inconclusive (106, 
107). 
Collectively, prostacyclin is attributed detrimental (inflammatory and pain mediating) or 
beneficial (vasodilating, anti-thrombotic, and anti-cancer) actions depending on the biological 
context. 
TXA2 
TXA2 is a potent platelet activator and vasoconstrictor. It signals through the Gq-coupled TP 
receptor that exists in two isoforms (TPα and TPβ). While platelet are the dominant source of 
TXA2 production, macrophages and neutrophils can also produce TXA2. Mice lacking the TP 
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receptor are fully viable but display cardiovascular alterations. Thomas et al. reported increased 
bleeding time and delayed aggregation response in TP deficient mice (108). The authors 
showed that these mice resisted arachidonic acid-induced shock, which resulted in 
cardiovascular collapse and sudden death in WT mice. Francois et al. reported less cardiac 
hypertrophy caused by hypertension in mice lacking the TP receptor (109, 110). In 
inflammation, deletion of the TP receptor protects mice from LPS-induced acute renal failure 
(111). TXA2 is also implicated in cancer progression (112). For example, increased TXAS 
protein expression correlated with tumor progression in prostate cancer (113) and metastasis in 
lung cancer (114) but TXAS mRNA (TBXAS1) expression was reported lower in high-grade 
tumors compared to low-grade tumors in breast cancer (115). 
 
 
 
 
Figure 3. Biosynthesis of the main prostanoids. Reprinted with permission from (116).   
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1.4 CLINICAL USE OF NSAIDS 
The biological set-up of terminal synthases and receptor expression patterns enables complex 
signaling with prostanoids. This has major implications in inflammation and cancer, where 
small molecule inhibitors can manipulate prostanoid biosynthesis. NSAIDs, like aspirin and 
ibuprofen, are widely used drugs to treat pain and inflammation. Their analgesic and anti-
inflammatory effects are mainly mediated by non-selective blockage of PGE2 production via 
inhibition of COX-1 and/or COX-2 (117), a mechanism that Sir John Vane was awarded the 
Nobel Prize in Physiology or Medicine for in 1982. This section will introduce the reader to 
the COX enzymes and the clinical use of NSAIDs. 
1.4.1 COX-1 and COX-2 
The human COX enzymes are similar in size, structure, and catalytic function (10). COX-1 is 
576 amino acid long (71 kDa) and COX-2 is 581 amino acid long (73 kDa), and they have 60% 
sequence homology. The sequence homology for each isoform between different mammalian 
species is about 90% (118). There is a lack of interspecies difference in the active site, meaning 
NSAIDs with activity towards human COX also inhibit for example rat and mice enzymes. 
Both COX enzymes have a catalytic site for the generation of PGG2 from AA and a peroxidase 
active site for the conversion of PGG2 to PGH2. COX-1 and COX-2 function as homodimers; 
although, only one COX monomer is needed for PGH2 production and the other monomer 
appears to have allosteric functions (119). While COX-1 is regarded as constitutively expressed 
for basal prostanoid synthesis, COX-2 is normally absent in most cells and tissues but induced 
during pro-inflammatory stimuli and therefore viewed as the key isoform for the induced 
prostanoid production. However, this is a simplified view. 
It was early concluded that COX-1 and COX-2 are expressed on the mRNA level at 
physiological condition but with different tissue-specific expression (120). The isoforms have 
different tissue distribution and cell localization on the protein level. COX-1 is expressed in 
nearly all tissues with a preferential protein localization to blood vessels, smooth muscle cells, 
and platelets. COX-2 is mainly expressed in brain, kidney, lung, and thymus (121). 
The isoforms are differently regulated at transcription, translation, and protein levels (122, 
123). Indeed, PTGS2 (gene encoding COX-2) is transcribed upon inflammatory and 
proliferative stimuli, and the mRNA carries an instability sequence in the 3’-untranslated 
region. This suggests that COX-2 is the dominant isoform during inflammation and cancer, 
which is also concluded in many studies. However, mice lacking COX-1 showed decreased 
inflammation in a model of ear edema (124). COX-2 deficiency was not protective in 
carrageenan-induced paw edema in rats, where inhibition of both COX-1 and COX-2 was 
needed to reduce paw swelling (125). Genetic deletion of COX-1 decreased severity while 
genetic deletion of COX-2 increased severity in a mice model of neuroinflammation (126, 127). 
Deficiency in COX-1, and not COX-2, is protective in the autoantibody-driven K/BxN serum-
transfer arthritis model in mice (99). In contrast, genetic deletion or pharmacological inhibition 
of COX-2, and not COX-1, is protective in the CIA model in mice (128, 129). In cancer models, 
COX-1 or COX-2 deletion decreased tumors in small intestine to the same degree in the 
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ApcMin/+ mice model (130), while deletion of either COX-1 or COX-2 had no effect on tumor 
incidence in a mice model of colitis-associated colon cancer (AOM/DSS model) (131). 
Nonetheless, repeated injection of AOM alone caused tumor formation in COX-1 deficient 
mice but not in COX-2 deficient mice. These studies highlight that both isoforms are important 
during inflammation and cancer depending on the disease model. 
1.4.2 Drug history: From aspirin to coxibs 
Aspirin has been a product for over a century. It is not only used to treat fever, pain, and 
inflammation but low-dose aspirin is a successful strategy to prevent cardiovascular events 
(myocardial infarction, stroke, and vascular death) (132) and colorectal cancer (133). Aspirin 
is an irreversible inhibitor of COX enzymes, as it acetylates Ser-530 on COX-1 and Ser-516 
on COX-2. Acetylated COX-1 has no activity while acetylated COX-2 has altered substrate 
specificity and activity. Acetylated COX-2 can metabolize AA into 15(R)-HETE (134), which 
is an agonist for PPARβ/δ (135) that controls cell differentiation and lipid metabolism with 
implications in inflammation and cancer (136). In addition, acetylated COX-2 produces 
specialized pro-resolving lipid mediators (SPMs) including lipoxin A4, resolvin D1, and 
resolvin D3 that are pro-resolving and anti-cancer (137-139). Low-dose aspirin mediates anti-
thrombotic effect via the irreversible inhibition of COX-1 in platelets, which suppresses TXA2 
biosynthesis without affecting prostacyclin production (140, 141). This shifts the balance 
between vasoconstrictive TXA2 and vasodilative prostacyclin. Aspirin is rapidly hydrolyzed 
into salicylic acid and acetic acid in vivo, where salicylic acid is equally potent in inhibiting 
PGE2 production in pouch exudate in rats but less potent in blocking TXA2 biosynthesis in 
human clotting blood (142). The primary effect on platelet COX-1 by low-dose aspirin is due 
to the presence of aspirin in portal blood (from stomach and small intestine to the liver) before 
hydrolysis by plasma esterases and liver carboxylesterase-2 (first-pass effect) (143, 144). 
Two landmark articles in 1991 concluded that regular use of aspirin correlated with decreased 
incidence of colorectal cancer (145, 146). These were the first epidemiological associations 
that aspirin is protective in cancer. Subsequent epidemiological studies have showed that 
aspirin intake correlated with decreased incidence and mortality in lung cancer (147), and 
recently a large meta-analysis showed that regular aspirin users have a lower risk for overall 
cancer (148). Low-dose aspirin also increases survival following treatment of lung cancer and 
rectal cancer (149, 150). However, studies in the 1980s showed an increased risk of Reye´s 
syndrome (a progressive and lethal brain disease that starts in connection to recovery from a 
viral infection) in children taking aspirin during a fever (151), and this has restricted the use of 
aspirin in children. In addition, low-dose aspirin increases the risk for gastrointestinal bleeding 
(132, 152-154). 
Multiple NSAIDs entered the market during the 20th century such as phenylbutazone in the 
1940s, fenamates in the 1950s, acetic acid derivatives (e.g. indomethacin, diclofenac) in the 
1960-1970s, propionates (e.g. naproxen, ibuprofen) in the 1970s, oxicams in the 1980s, and 
coxibs (e.g. celecoxib) in the 1990-2000s. In the early 1990s, several landmark papers on 
NSAIDs were published. As mentioned above, regular use of aspirin was observed protective 
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against colorectal cancers (145, 146). However, aspirin was well-documented to cause gastric 
damage since many decades due to early work by Arthur Henry Douthwaite, and it was 
concluded by Langman et al. in 1994 that all traditional NSAIDs caused gastrointestinal 
bleeding (155). Two laboratories identified the gene encoding COX-2 in 1991 (156, 157),  
which was found induced in several types of cells upon pro-inflammatory stimuli (reviewed in 
(158)). Selective inhibition of COX-2 quickly became an anticipated therapeutic strategy, 
which was envisioned to spare the gastrointestinal adverse effects thought to be mediated via 
COX-1 inhibition, and be more efficient than existing NSAIDs to treat inflammation (159-
162). 
Indeed, the selective COX-2 inhibitor celecoxib (100 mg twice daily) showed good analgesic 
and anti-inflammatory responses in treatment of osteoarthritis and rheumatoid arthritis with 
reduced incidence of gastrointestinal events associated with dual COX-1/2 inhibitor naproxen 
(163). This was confirmed in a large clinical trial (n=8069), where high dose celecoxib (400 
mg twice daily) showed lower incidence of gastrointestinal toxicity compared to ibuprofen 
(800 mg three times daily) or diclofenac (75 mg twice per day) in patients suffering from 
osteoarthritis or rheumatoid arthritis (164). Celecoxib became the first selective COX-2 
inhibitor (coxib) to be approved by the FDA in 1998. In a clinical trial on colon cancer, 
celecoxib inhibited growth of adenomatous polyps in familial adenomatous polyposis (165). 
The coxib rofecoxib (50 mg daily) was equally efficient as naproxen (500 mg twice daily) in 
treating rheumatoid arthritis as assessed by global disease activity score and modified health 
assessment questionnaire, where patients receiving naproxen where twice as likely to suffer 
from gastrointestinal events (166). However, the incident rate for myocardial infarction was 
four times higher in patients receiving rofecoxib compared to naproxen, although there was no 
difference in rate of death from cardiovascular causes between the two groups. 
Rofecoxib was used as prevention treatment in a clinical trial on colorectal adenoma but this 
was terminated when the increased rate of cardiovascular events (myocardial infarction and 
ischemic cerebrovascular events) was detected (167). Another study demonstrated increased 
risk for cardiovascular events (myocardial infarction, cardiac arrest, stroke, and pulmonary 
embolism) after receiving the selective COX-2 inhibitors parecoxib or valdecoxib compared to 
placebo in patients that had undergone cardiac surgery (168). Moreover, increased 
cardiovascular risk (myocardial infarction, stroke, and cardiac arrest) was observed with 
celecoxib used as prevention treatment in colorectal adenoma (169). The increased risk for 
cardiovascular events led to the withdrawal of many coxibs and FDA issued a boxed warning 
for the use of celecoxib and other NSAIDs in 2004 (170). Multiple observational studies (171-
175) and meta-analyses (176-180) have confirmed that coxibs, diclofenac, indomethacin, and 
to less extent ibuprofen, increase the risk for cardiovascular events. Naproxen is the safest non-
aspirin NSAID in terms of cardiovascular risk, although naproxen doubles the risk of heart 
failure (176). A large cohort study (181), a large case-control study (182), and multiple meta-
analysis (183, 184) collectively show that ibuprofen has low, naproxen and diclofenac have 
intermediate, and indomethacin has high gastrointestinal toxicity. 
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One additional concern with NSAIDs that act on COX-1 is that a subset of asthmatic patients 
is sensitive to these drugs and develop non-allergic reactions (185), called NSAID-exacerbated 
respiratory disease (N-ERD). The pathogenesis is multifactorial, as these patients have 
decreased basal concentration of protective PGE2 in the airways (186), increased expression of 
LTC4 synthase (for biosynthesis of bronchoconstrictor LTC4) in bronchial biopsies (187), and 
increased basal concentration of LTE4 (LTC4 metabolite) in urine, saliva, induced sputum, and 
ex vivo blood (188). Patients with aspirin-intolerant asthma have increased concentration of 
LTC4 in bronchoalveolar fluid (187) together with increased concentration of urinary LTE4 and 
urinary PGD2 metabolite 9α,11β-PGF2 upon aspirin intake (188), compared to patients with 
aspirin-tolerant asthma. 
Lastly, NSAIDs are associated with renal complications. This includes peripheral edema and 
hypertension from sodium retention (189) and increased risk of renal failure (190). The 
increased risk for any severe adverse effects can be considered small for the general population, 
when NSAIDs are administered at low doses and for short periods. Yet, the risks may be greatly 
increased in certain patient groups with high age, systemic disease, and other ongoing 
treatments such as patients suffering from rheumatoid arthritis (191), where high NSAID doses 
are used.  
Apart from the many protective associations, there are two main lessons learned from 
observational studies, clinical trials, and meta-analyses on NSAIDs: first, dual COX-1/2 
inhibitors cause primarily gastrointestinal bleeding and second, selective COX-2 inhibitors 
increase the risk of serious cardiovascular events (Table 1). 
 
NSAID COX selectivity Therapeutic uses Severe adverse effects 
Indomethacin COX-1 > COX-2 Analgesic, anti-pyretic, anti-
inflammatory 
Gastrointestinal bleeding (high), 
N-ERD  
Aspirin COX-1 > COX-2 Analgesic, anti-pyretic, anti-
inflammatory, anti-thrombotic 
(low-dose), prevent cancer 
Gastrointestinal bleeding, Reye’s 
syndrome, N-ERD 
Naproxen COX-1/2 Analgesic, anti-pyretic, anti-
inflammatory 
Gastrointestinal bleeding 
(intermediate), N-ERD 
Ibuprofen COX-1/2 Analgesic, anti-pyretic, anti-
inflammatory 
Gastrointestinal bleeding (low), 
stroke, N-ERD 
Diclofenac COX-1 < COX-2 Analgesic, anti-pyretic, anti-
inflammatory 
Gastrointestinal bleeding 
(intermediate), myocardial 
infarction, stroke, N-ERD 
Celecoxib COX-1 < COX-2 Analgesic, anti-inflammatory, 
prevent cancer 
Myocardial infarction, stroke, 
gastrointestinal bleeding 
Rofecoxib COX-1 <<< COX-2 Withdrawn since 2004 Myocardial infarction, stroke 
Table 1. Overview of NSAIDs. Please see the main text for references.  
  19 
1.4.3 Adverse effects: The relationship between COX-1 and COX-2 
Early research on COX deficient mice showed that mice lacking COX-1 display minor 
prostaglandin production throughout tissues but are fully viable (124). The mice showed 
decreased platelet aggregation and no signs of gastrointestinal damage. This supports the 
beneficial role of low-dose aspirin (irreversible inhibition of COX-1), but it does not support 
that gastrointestinal damage is caused by COX-1 deficiency. Instead, this points towards 
compensatory effect of COX-2 in these mice as the dual COX-1/2 inhibitor indomethacin 
induced gastrointestinal erosion in WT and COX-1 deficient mice (124). This effect of 
indomethacin on gastric erosion was later confirmed in rats, where the authors also 
demonstrated that neither celecoxib nor selective COX-1 inhibitor SC-560 alone caused 
gastrointestinal damage, but they did in combination (192). The many PG-mediated 
mechanisms for NSAID-induced gastrointestinal damage include reduced blood flow, 
decreased cell proliferation, increased gastric acid secretion, decreased bicarbonate secretion, 
and decreased mucus production (reviewed in (193)). The gastroprotective role of PGE2 is 
evident from clinical studies where misoprostol (a PGE1 analog that can bind EP2, EP3, and 
EP4) prevented NSAID-induced gastrointestinal damage (194-196). Then again, PGE2 
concentration in stomach tissue was decreased with SC-560 but not further decreased with 
celecoxib in the rat study above (192). This suggests that alternative non-PG mediated 
mechanisms may contribute to NSAIDs-induced gastric injury (197, 198), such as redirection 
of AA from prostanoids to LTs. Reduction in gastroprotective PGE2 worsen gastrointestinal 
damage, where it is has been proposed that NSAIDs themselves may drive the initiation of 
the damage via biochemical effects including increase in intestinal permeability and intestinal 
inflammation (199, 200). 
COX-2 deficient mice display failure in several reproductive events in early pregnancy (201). 
In addition, genetic deletion of COX-2 disrupts postnatal kidney development (202, 203), 
causes cardiac fibrosis (203), and increases blood pressure and accelerates thrombosis (204, 
205). As presented above, multiple NSAIDs and coxibs increase the risk for serious 
cardiovascular events. The established dogma behind the side effects imposed by NSAIDs is 
reduction in vasodilative prostacyclin from endothelial-derived COX-2 while 
vasoconstrictive TXA2 production continues from platelet-derived COX-1 (206). Indeed, 
healthy volunteers taking the coxibs nimesulide (207), celecoxib (208), or rofecoxib (209) 
have reduced urinary prostacyclin metabolite 2,3-dinor-6-keto PGF1α (PGIM) but not urinary 
TXA2 metabolite 11-dehydro TXB2. High-dose aspirin (207) and normal dose ibuprofen 
(208), indomethacin (209), naproxen (210), and diclofenac (211) reduce both PGIM and 11-
dehydro TXB2, suggesting that the balance and not the absolute production of prostacyclin 
and TXA2 is important in the increased risk of cardiovascular events. Nonetheless, the 
literature suggest that naproxen is not associated with major vascular events while 
indomethacin, ibuprofen, and diclofenac are (176, 179). 
The relative contribution of COX-1 and COX-2 for endothelial prostacyclin production in 
human is debated in the literature (212, 213). There may be additional mechanism(s) for the 
cardiovascular hazard seen with NSAIDs. For example, Ahmetaj-Shala et al. proposed a role 
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of COX-2 in the kidneys that affected vessel tone via regulation of asymmetric 
dimethylarginine (ADMA) (214), which is an endogenous inhibitor of endothelial NO 
synthase. The aortic vessels from mice lacking COX-2 were less responsive to acetylcholine-
induced relaxation compared to control mice in an ex vivo model. The authors showed 
increased levels of ADMA in plasma from COX-2 KO mice, parecoxib treated mice, and 
from humans taking celecoxib or naproxen. Increased levels of ADMA in plasma is in turn 
linked with all-cause mortality in man (215). In other words, since naproxen reduces urinary 
PGIM concentration (210) and increases ADMA concentration in plasma (214), this should 
favor cardiovascular hazard in man with both the prostacyclin hypothesis and the ADMA 
hypothesis. Then again, there is little or no evidence that naproxen increases the rate of 
cardiovascular events. Even if the causes for increased cardiovascular events with NSAIDs 
are not fully understood, the consensus is that non-aspirin NSAIDs (except naproxen) are 
cardiovascular toxic. 
Both COX isoforms are important for the generation of prostanoids in health and disease. As 
described earlier, there is little evidence for compensatory mechanism in knockout studies. 
Replacing PTGS2 with PTGS1 (encoding COX-1) does not fully restore prostacyclin 
production nor does it rescue reproductive function or renal complications (hypertension) in 
knock-in studies (216, 217). However, complete deletion of either COX-1 or COX-2 had no 
effect on pain transmission in hot plate assay in mice but COX-1 deficient heterozygous 
showed less pain (218). This suggests that COX-1 can compensate for COX-2 but COX-2 
cannot compensate for partial loss of COX-1 in rapidly transmitted pain. At the same time, 
the number of writhing response following acetic acid was lower in COX-1-/- and COX-1+/- 
male mice and COX-1-/-, COX-1+/-, and COX-2+/- female mice. This suggests that COX-1 
can compensate for COX-2 in slowly transmitted pain in male mice but not in COX-2 
deficient heterozygous female mice. 
One important note is that AA is not the only substrate for COX enzymes. For example, 
endocannabinoids and other free fatty acids such as eicosapentaenoic acid (20:5, ω-3), alpha-
linolenic acid (18:3, ω-3), gamma-linolenic acid (18.3, ω-6), and linoleic acid (18:2, ω-6) can 
all be metabolized by COX-1 and/or COX-2, where the selectivity is isoform specific (219). 
This adds to the complexity between the relative roles of the two enzymes, as metabolism of 
each substrate will generate distinct products that mediate different physiological and/or 
pathological responses.  
It is evident that NSAIDs cause gastrointestinal and/or cardiovascular adverse effects, 
especially at high doses used in treatment of rheumatoid arthritis. Inhibition on the COX level 
is a complex approach (220), as this blocks the production of multiple prostanoids that have 
both beneficial and detrimental effects depending on the biological context, and the inhibition 
may redirect AA from the COX pathway to the LOX (lipoxygenase) pathway. This may 
cause compensatory effects or introduce new effects, which is difficult to predict. In addition, 
the therapeutic uses and adverse effects associated with different NSAIDs are not simply 
explained by their relative selectivity towards the COX enzymes. Drug structure, 
bioavailability, half-life, and degree of inhibition over time are some of the important 
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parameters to consider in pharmacokinetics and pharmacodynamics studies when dissecting 
the cause(s) of adverse effects (221). In conclusion, targeting the COX pathway is an 
important and widely used therapeutic strategy but the many detrimental effects limit the use 
of NSAIDs. Selective inhibition of downstream mPGES-1 may be a safer option. 
1.5 MPGES-1 AS THERAPEUTIC TARGET 
1.5.1 Structure and catalytic function of mPGES-1 
The human terminal enzyme mPGES-1 was first cloned and characterized in 1999 (222). The 
rat and mouse mPGES-1 were described the year after (223). This is a 152 amino acid long and 
16 kDa large membrane protein, typically upregulated by inflammatory stimuli including IL-
1β, TNF-α, and LPS (222-227). A first low-resolution crystal structure was reported in 2008 
(228) and a high-resolution structure was reported in 2013 (229), showing that mPGES-1 is a 
homotrimer where each monomer consist of four transmembrane alpha-helices. Site-directed 
mutagenesis studies have concluded that Asp-49 and Arg-126 are important residues for the 
catalytic function of human mPGES-1 (230-232).  
1.5.2 Genetic deletion of mPGES-1 
The first mPGES-1 KO model was reported in 2002, in which mPGES-1 deficient peritoneal 
macrophages failed to produce PGE2 in response to LPS (233). Since then, genetic deletion 
of mPGES-1 has been the topic of numerous research investigations. Multiple subsequent 
studies have demonstrated that mPGES-1 is the key enzyme for the induced PGE2 production 
in peritoneal macrophages (103, 234-239). Mice lacking mPGES-1 are fully viable without 
altered phenotype at normal conditions (240). The basal PGE2 production was reported lower 
in stomach, spleen, brain, and kidney (234); however, unchanged basal production of PGE2 
in spleen and brain in mPGES-1 KO mice has been reported (236).  
Effect in arthritis models. Arthritis can be induced in mice via immunization with collagen 
or administration of autoantibodies towards collagen. This is monitored using the degree of 
paw swelling (thickness) and the clinical arthritis score, which includes redness and number 
of joints affected. Mice lacking mPGES-1 had reduced incidence and severity of disease in 
the CIA model (240, 241), as these mice failed to produce autoantibodies (241). Mice 
receiving intraperitoneal injection of stable PGE2 analog misoprostol had earlier onset and 
higher arthritis score in the CIA model (242). This is in line with that genetic deletion of 
COX-2 (129), pharmacological inhibition of COX-2 (128), and antagonist for EP2/EP4 (98) 
are reported protective in the CIA model. Treatment with EP4 antagonist was protective in 
the CIA model and in the glucose-6-phosphate isomerase-induced arthritis model in mice 
(243). It was reported in the same study that EP4 antagonism decreased complete Freund’s 
adjuvant (CFA)-induced inflammatory pain in rats. While these studies conclude that PGE2 
mediates arthritis in many models, contradicting results have been reported for mPGES-1 
deletion in the collagen antibody-induced arthritis (CAIA) model. Kamei et al. reported that 
mice lacking mPGES-1 had 50% reduced PGE2 production in paws and decreased disease 
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severity but similar incidence as WT mice (238). In contrast, Frolov et al. showed complete 
blockage of induced PGE2 production in the arthritic paws from mPGES-1 KO mice that 
coincided with increased neutrophil infiltration and increased incidence and higher arthritis 
score (244). In the K/BxN serum-transfer arthritis model in mice, mPGES-1 deletion 
decreased PGE2 production by >90% in joint tissues but this had no impact on the disease 
development (99). In addition, deletion of mPGES-1 did not affect bone loss or osteoarthritis 
but caused impaired fracture healing in a mice model of skeletal disorders (245). Apart from 
differences in mice strains and arthritis models, the difference in absolute PGE2 synthesis 
may be of importance for disease incidence and severity. The role of other prostanoids (like 
prostacyclin) needs to be considered. This is especially apparent in the K/BxN serum-transfer 
model, where prostacyclin (IP signaling) plays a role (99). In conclusion, experimental 
models suggest that mPGES-1 is important for development of autoimmune arthritis.  
Effect in cancer models. Genetic deletion of mPGES-1 is protective in multiple cancer 
models. The laboratory of Daniel W. Rosenberg has investigated the contribution of mPGES-
1 in intestinal tumorigenesis. They reported that ApcΔ14/+ mice developed fewer and smaller 
intestinal and colonic polyps upon mPGES-1 deletion (246). The KO mice had decreased 
PGE2 production in the small intestine and colon without altered production of other 
prostanoids. In addition, mice lacking mPGES-1 had increased amount of endothelial 
(CD31pos) cells in polyps but this was not associated with formation of new vessels, 
suggesting that PGE2 is important for vascular tube formation. The authors showed in the 
same study that KO mice had 50% decreased amount of aberrant crypt foci in AOM-induced 
colon carcinogenesis model. This was repeated in another study, where the anti-cancer effect 
from mPGES-1 deletion coincided with an increase in cytotoxic T cells (CD8pos) and MDSCs 
(Gr-1posCD11bpos) with a decrease in Tregs (CD4posFoxp3pos) in colon-draining mesenteric 
lymph nodes, suggesting modulation of immunoregulatory responses (247). The group has 
recently demonstrated that although lack of mPGES-1 is protective in intestinal cancer, 
deletion of mPGES-1 caused more severe DSS-induced injury (colitis) and impaired recovery 
in ApcMin/+ mice (248). The KO mice had fewer tumors in the small intestines and unaltered 
tumor burden in the colon at baseline. Following DSS treatment, mice lacking mPGES-1 had 
even fewer tumors in the small intestine but not in the colon. These mice had altered 
eicosanoid production at baseline and upon DSS treatment, both in the small intestine and 
colon. Most notable alterations in the small intestine were the reduction in PGE2, 6-keto 
PGF1α, and PGF2α at baseline. Following DSS treatment, PGD2 was increased and PGF2α 
remained decreased compared to WT mice in the small intestine. This suggests that induction 
of damage (inflammation) decreases tumor load in the small intestine in mPGES-1 deficient 
mice, perhaps via increased PGD2 formation. Contradicting results have been reported by 
Elanders et al., who showed that ApcMin/+ mice lacking mPGES-1 had more and larger tumors 
in the small intestine despite also displaying a redirection of PGH2 from PGE2 to PGD2 in 
the tumor tissues (249). While these studies were performed on the same mice background, 
the study length (10 weeks vs. 18 weeks) may contribute to the differences in prostanoid 
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profiles and consequently tumor progression. It is possible that lack of mPGES-1 is protective 
in the early-mid phase of tumorigenesis but detrimental in the late phase. 
Sasaki et al. confirmed that mPGES-1 deficiency decreased the total amount and size of 
colorectal polyps in AOM-induced colon cancer (48, 103), whereas PGIS deficiency 
increased the amount of large polyps (103). The authors showed increased formation of 
prostacyclin in the tumors from mPGES-1 KO animals, highlighting anti-cancer properties 
of prostacyclin. Kamei et al. demonstrated that Lewis lung carcinoma cells (LLCCs) deficient 
in mPGES-1 formed smaller tumors in WT mice (250). They also showed that mice lacking 
mPGES-1 had slower growing LLCC tumors in a xenograft model and less metastasis (lung 
weight). The expression of VEGF was reduced in tumor and lung tissue in the different 
models, suggesting less angiogenesis to be a main mechanism for the protective effects upon 
mPGES-1 deletion. Kamata et al. used bone marrow chimeric mice to demonstrate that mice 
lacking mPGES-1 in bone marrow-derived cells had reduced LLCCs tumor growth with less 
VEGF expression and angiogenesis in the tumors (251). The anti-angiogenic effect upon 
mPGES-1 deletion was reproduced in a model of lung metastasis formation in prostate cancer 
(252) and Howe et al. showed that mice lacking mPGES-1 had reduced angiogenesis and 
tumor growth in a transgenic mouse model of breast cancer (253).  
Isono and co-workers investigated bone cancer growth and cancer-related pain upon injection 
of LLCCs in the bone marrow (254). Mice lacking mPGES-1 had slower tumor growth and 
less bone cancer pain. Moreover, tumors of A549 lung cancer cells or DU145 prostate cancer 
cells lacking mPGES-1 grow slower in xenograft mice (255). Olesch and colleagues 
demonstrated that mPGES-1 deficiency decreased tumor burden (weight and number of 
tumors) in transgenic PyMT mice that spontaneously develop breast cancer (256). They 
showed that these tumors had increased amount of CD80pos and decreased amount of 
CD206pos resident macrophages, suggesting a change in macrophage polarization towards 
anti-cancer M1 phenotype in the tumors. Zelenay et al. deleted mPGES-1 and mPGES-2 in 
BrafV600E melanoma cells and showed that these cells were spontaneously rejected in 
immunocompetent mice but grew in immunodeficient mice (52). While transgenic mice 
overexpressing COX-2 and mPGES-1 developed tumors in the gastric tract (257, 258), 
targeted overexpression of mPGES-1 in lung epithelial cells with increased PGE2 production 
was not sufficient to induce lung cancer (259). These studies conclude that PGE2 production 
from both stroma cells and cancer cells mediate tumor growth via several mechanisms, and 
that blocking of COX/mPGES-1/PGE2 pathway is a therapeutic strategy in cancer.  
Redirection of PGH2. Deletion of mPGES-1 can cause an increase in other prostanoids. This 
is dependent on the biological context. Lack of mPGES-1 results in decreased urinary 13,14-
dihydro-15-keto PGE2 (PGEM) and increased urinary PGIM in mice (60, 61, 205). Peritoneal 
macrophages from mice lacking mPGES-1 showed increased prostacyclin, TXB2, and/or 
PGD2 when challenged with LPS (103, 234-239). Mouse embryo fibroblasts from mice 
lacking mPGES-1 had enhanced activation of PPARγ at basal and IL-1β induced conditions, 
which can be explained by redirection of PGH2 from PGE2 biosynthesis to 15d-PGJ2 
production via PGD2 (260). Moreover, dendritic cells from mPGES-1 KO mice also showed 
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increased production of PGD2 upon LPS treatment (261). In a model of acute inflammation 
(air pouch), mPGES-1 KO mice showed no induced production of PGE2 but elevated 
formation of TXB2 in pouch exudates, although this had no impact on pouch volume or cell 
infiltration (262). Mice lacking mPGES-1 display reduced inflammatory pain in the acetic 
acid writhing assay (238) and reduced mechanical allodynia and thermal hyperalgesia 
following nerve damage in a model of neuropathic pain (263). However, mPGES-1 deletion 
cause no change in nociception in the hot plate assay or the formalin assay (237, 240). This 
can be due to increase in prostacyclin after mPGES-1 deletion. It is therefore important to 
monitor the general prostanoid production after mPGES-1 deletion, as other prostanoids may 
increase in concentration and compensate for PGE2 or even introduce new phenotypes. 
Models of cardiovascular diseases. The increase in prostacyclin following mPGES-1 
deletion is of special interest for the cardiovascular system. The laboratory of Garret A. 
FitzGerald has investigated the role of mPGES-1 in models of cardiovascular disease. In 
contrast to COX-2 deficient mice, mice lacking mPGES-1 have no altered blood pressure and 
no promotion of thrombosis (205). In addition, mPGES-1 deletion retarded atherosclerosis 
(60), protected against angiotensin II-induced abdominal aortic aneurysm formation and 
oxidative stress in hyperlipidemic mice (61), and decreased proliferation and migration of 
vascular smooth muscle cells following vascular injury (264). The protective effect in 
atherosclerosis is specific for myeloid cells since removal of mPGES-1 in vascular smooth 
muscle cells or endothelial cells had no effect in this model (265). In the model of vascular 
injury, deletion of mPGES-1 in vascular smooth muscle cells or endothelial cells caused 
worse response (intimal thickening, vascular stenosis, and leukocyte infiltration) while 
deletion in myeloid cells was protective (239). The group has also showed that while 
mPGES-1 deletion resulted in redirection of PGH2 from PGE2 to other prostanoids in the 
lungs, this was neutral in regards to bronchial tone during baseline or ozone-induced airway 
inflammation (266).  
A protective response upon mPGES-1 deletion was reported in a model of stroke (62). In 
addition, Wu et al. showed that mPGES-1 KO mice displayed no increase in ischemic 
myocardial damage after myocardial infarction, which was in contrast to inhibition of COX-
2 in WT mice (267). The same authors demonstrated that the use of an IP receptor antagonist 
blocked the protective response from mPGES-1 deletion in acute cardiac ischemic damage 
after coronary occlusion in mice (268). However, Degousee et al. reported that mPGES-1 
deficient mice had more severe complications (left ventricular dilation and impaired left 
ventricular contractile function) after myocardial infarction, but no increase in mortality 
(269). Deletion of mPGES-1 worsened the outcome in a model of intracranial aneurysm (270) 
and a protective role of mPGES-1 in maintaining cardiac function after angiotensin II 
infusion has been reported (271). These studies highlight that mPGES-1, for the most part, 
drives many detrimental processes in models of cardiovascular disease. 
Consequences on renal functions. Given the adverse effects in renal functions observed 
with NSAIDs, the laboratory of Tianxin Yang has investigated the role of mPGES-1 in the 
kidneys. Mice deficient in mPGES-1 showed no altered renal functions (normal water and 
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sodium balance) at baseline but altered responses in different disease models. They reported 
that genetic deletion of mPGES-1 has detrimental impact on sodium balance and blood 
pressure after salt loading and angiotensin II infusion (272) or treatment with 
deoxycorticosterone acetate (273). Treatment with sodium-retaining compound aldosterone 
had no effect on WT mice but KO mice displayed increased sodium balance with weight gain 
(274). KO mice were unable to excrete water following acute water loading (275), and the 
mice were unable to excrete sodium after dehydration (276). Moreover, removal of mPGES-
1 made mice resistant to lithium-induced polyuria (277). In a mice model of chronic kidney 
disease that is characterized by loss of functional renal mass (or glomerular filtration rate), 
deletion of mPGES-1 resulted in deficient waste excretion (278). The KO mice had milder 
inflammation but worse anemia compared to WT mice after chronic renal failure. These 
studies highlight a significant role of kidney mPGES-1 in handling of sodium and water 
balance after induced challenge but not at baseline.  
Consequences on wound healing. The reduced angiogenesis upon mPGES-1 deletion in 
cancer models (250-253) is not exclusive for tumors since mPGES-1 deficient mice have 
delayed wound healing of gastric ulcers after challenge with acetic acid (279). Similar to EP4 
deficient mice (40), mPGES-1 KO mice developed more severe ulcerative colitis upon DSS 
treatment (280). In addition, spontaneous ulcerations have been reported in one study with 
mice lacking mPGES-1 (247). These studies support a protective role of mPGES-1 in gastric 
ulceration. 
Role of mPGES-1 in additional models. Genetic deletion of mPGES-1 blocks induction of 
fever (281, 282), specifically via brain endothelial cells (283). Mice lacking mPGES-1 
displayed no negative feedback in IL-1β and TNF-α production upon repeated LPS injections 
in a model of neuroinflammation (284), suggesting that mPGES-1 derived PGE2 in the initial 
phase of inflammation is needed for limitation of inflammation in later phases. Moreover, 
deletion of mPGES-1 is protective in mice models of Alzheimer’s disease (285, 286) and 
Kihara et al. reported that mPGES-1 mediated disease features in experimental autoimmune 
encephalomyelitis (EAE), with implications in multiple sclerosis (58). In addition, while 
tumor growth was not reduced, two studies have investigated the role of mPGES-1 in cancer-
induced anorexia in mice. One study showed a protective effect while the other showed a 
neutral effect upon mPGES-1 deletion (287, 288). Matsuda et al. concluded that mPGES-1 
increased lymphangiogenesis via VEGF in a model of peritonitis, where its deletion resulted 
in less lymphangiogenesis and slower draining rates (289). Lastly, mPGES-1 deletion 
increased survival of mice following hypoxia (290). 
Role of mPGES-2 and cPGES in animal models. While studies have investigated the 
physiological and pathological roles of mPGES-2 and cPGES, these enzymes are up to date 
not considered as druggable targets compared to mPGES-1. Mice lacking mPGES-2 have no 
altered phenotype or reduction in basal PGE2 production in analyzed tissues, and mPGES-2 is 
not regulated by inflammatory stimuli (one exception is increased expression in colorectal 
cancer (291)). Deletion of cPGES decreased basal PGE2 production and loss of cPGES is 
perinatal-lethal in mice (reviewed in (280)). Expression of cPGES is mostly unaffected by 
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inflammatory stimuli, but active downregulation of cPGES expression results in reduced 
nociceptive response in zymosan-induced thermal hyperalgesia and formalin assay in rats 
(292). The general lack of disease associations for these enzymes may be both a cause and 
effect of that these enzymes are understudied compared to mPGES-1. Future studies will reveal 
whether these terminal synthases could be druggable. 
Summary of mPGES-1 deletion. The protective effects of mPGES-1 deletion depends on 
the biological setting. Lack of mPGES-1 limits inflammation and decreases tumor growth. 
In addition, deletion of mPGES-1 is neutral or even beneficial in cardiovascular aspects 
compared to COX-2 deficiency. However, consequences on renal homeostasis and wound 
healing (gastric ulceration) should be taken into account. These results are the fundaments 
for the development of mPGES-1 inhibitors.  
1.5.3 Development of mPGES-1 inhibitors 
Merck reported the first selective mPGES-1 inhibitors in 2005 (293). Selectivity is based on 
the degree of inhibition of recombinant mPGES-1 over other terminal synthases and/or COX 
enzymes in activity assays. The compounds inhibited recombinant mPGES-1 with IC50 
values of 0.003-0.007 µM, and also decreased PGE2 production in IL-1β induced A549 cells 
with IC50 of 0.27-0.49 µM (2% serum) and 5.8-8.0 µM (50% serum). However, the inhibitors 
showed no inhibition of PGE2 biosynthesis in LPS-induced human whole blood.  
The first selective mPGES-1 inhibitor that showed activity in human whole blood was MF63, 
first disclosed in 2007 (294) and later fully characterized in 2008 (295). It inhibited 
recombinant human mPGES-1 (activity assay) with IC50 of 0.001 µM and decreased induced 
PGE2 production in IL-1β treated A549 cells (2% serum) with IC50 of 0.046 µM. MF63 
blocked induced PGE2 production in LPS treated human whole blood with IC50 of 1.3 µM. 
Moreover, guinea pigs treated with MF63 had decreased fever (LPS-induced pyresis) and 
decreased pain (LPS-induced thermal hyperalgesia and monosodium iodoacetate-induced 
incapacitance, which is a model of osteoarthritis pain). While MF63 is a potent inhibitor 
towards human and guinea pig mPGES-1, it lacks activity towards rat and mice enzyme. 
Nonetheless, the authors showed in human mPGES-1 knock-in mice that MF63 decreased 
LPS-induced hyperalgesia and PGE2 formation in an air pouch model. MF63 decreased 
stomach PGE2 formation and this did not cause gastrointestinal toxicity. This is a landmark 
publication, demonstrating that selective inhibition of mPGES-1 is a feasible therapeutic 
strategy to relive inflammatory pain. 
Several mPGES-1 inhibitors have since been described. Merck followed-up on the success 
of MF63 and reported two substituted MF63-like compounds (named 26 and 44) with 
increased potency in human whole blood (IC50 of 0.14 µM and 0.20 µM) that also reduced 
hyperalgesia in guinea pig (296). Bruno et al. reported compound AF3442 to inhibit 
recombinant human mPGES-1 (IC50 of 0.06 µM) and it displayed activity in human whole 
blood (IC50 of 0.41 µM). AF3442 also decreased PGE2 formation in LPS-induced human 
monocytes with no redirection towards other prostanoids (297), which is in contrast to the 
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effect observed upon genetic deletion of mPGES-1 in mouse peritoneal monocytes (103, 234-
238). Pfizer disclosed multiple mPGES-1 inhibitors in 2010 (298). The most potent was PF-
9184, which inhibited recombinant human mPGES-1 with IC50 of 0.17 µM but it was less 
potent in human whole blood with IC50 of 5 µM (299). Merck disclosed additional mPGES-
1 inhibitors in 2010 and 2011, which potently inhibited recombinant mPGES-1 (IC50 of 0.001 
µM) but the inhibitors displayed large decrease in potency in human whole blood (IC50 of 
1.6-2.1 µM) (300, 301). 
Finetti and colleagues were the first to demonstrate that inhibition of mPGES-1 replicated 
genetic deletion of mPGES-1 in terms of anti-cancer activity, specifically via less 
proliferation and angiogenesis (302). Treatment with mPGES-1 inhibitor AF3485 decreased 
epidermal growth factor receptor (EGFR) signaling and VEGF expression in vitro and in 
vivo, which limited tumor growth in mice xenografts of skin cancer A431 cells. Compound 
7 (FR20) and derivatives thereof were reported to inhibit mPGES-1 in broken cell assay from 
human HeLa cells, mouse RAW 264.7 cells, and mouse NIH cells (IC50 values of 0.13, 8.4, 
and 10.7 µM, respectively) (303). However, FR20 displayed poor inhibition in human whole 
blood (51% residual production of PGE2 at 100 µM).  
In 2013, several publications with new mPGES-1 inhibitors were published. Pfizer 
characterized PF-4693627 that inhibited recombinant human mPGES-1 with IC50 of 0.003 
µM (304, 305). This compound was equally efficient to naproxen in reducing PGE2 
production in an air pouch model in guinea pigs when administered at the same dose. 
However, it was about 100-fold more potent than naproxen since the plasma concentration 
was 1.2 µM for PF-4693627 and 154 µM for naproxen. AstraZeneca in collaboration with 
Uppsala University disclosed AZ’0908 as an mPGES-1 inhibitor but they presented only 
pharmacokinetics and no pharmacodynamics results (306). Dainippon Sumitomo Pharma 
reported multiple imidazoquinoline derivatives, where the most promising candidate was 
compound 39 that inhibited recombinant mPGES-1 with IC50 of 0.0041 µM and PGE2 
production from A549 cells with IC50 of 0.033 µM (307, 308). Hanke et al. reported several 
benzenesulfonamide derivatives with activity towards both human and murine enzymes 
(309). Compound 28 decreased PGE2 formation (%-inhibition at 5 µM) in broken cell assay 
from human HeLa cells (76%, IC50 of 13.8 µM) and mice RAW 264.7 (44%) and NIH cells 
(52%). This compound showed no inhibition of recombinant human COX-1 or COX-2 at 10 
µM. Then again, Compound 28 showed poor inhibition in human whole blood (70% residual 
production of PGE2 at 100 µM). 
Two additional compounds that displayed activity towards both human and rodent mPGES-
1 were reported in 2013. Compound II inhibited recombinant human and rat mPGES-1 with 
IC50 of 1.8 µM and 0.62 µM, respectively (310). This compound displayed no inhibition 
towards COX-1, COX-2, mPGES-2, or PGIS but partial inhibition of both PGDS isoforms 
and TXAS at high concentrations. Compound II inhibited PGE2, TXB2, and prostacyclin 
production by 50% in peritoneal macrophages from rat, without affecting the cell viability. 
General prostanoid reduction also occurred in vivo, where Compound II decreased both PGE2 
and PGD2 in air pouch exudates in rats. In addition, Compound II (100 mg/kg) slightly 
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reduces paw swelling in an adjuvant-induced edema model in rats. The follow-up inhibitor, 
Compound III (CIII), showed improved potency towards recombinant human mPGES-1 with 
IC50 of 0.09 µM (262). CIII was highly selective and only displayed partial inhibition of L-
PGDS at high concentrations. Moreover, CIII had an IC50 of ~10 µM in human whole blood. 
In contrast to AF3442 (297) and Compound II (310), CIII caused a shift from PGE2 to 
prostacyclin production in rat peritoneal macrophages. Neither genetic deletion of mPGES-
1 or treatment with CIII (10-100 mg/kg) affected exudate volume in an air pouch model, but 
CIII decreased the number of pouch cells (262). In another study, CIII decreased PGE2 in 
LPS induced peripheral blood mononuclear cells (PBMCs) and this caused no increased 
formation of other prostanoids (256). 
Glenmark Pharmaceutical Ltd. disclosed multiple potent inhibitors in 2014, where 
Compound 48 was reported as highly selective against recombinant mPGES-1 (IC50 of 0.005 
µM) and with activity in human whole blood (IC50 of 0.376 µM) (311). Several additional 
human mPGES-1 inhibitors have been described. One example is dimethylcelecoxib, which 
is a derivative of celecoxib that lacks activity to COX, inhibited mPGES-1 in recombinant 
assay (IC50 of 15.6 µM), HeLa cells (IC50 of 0.64 µM),and A549 cells (IC50 of 0.83 µM) 
(312). However, the reduction in PGE2 production is largely driven by inhibition of mPGES-
1 promotor activity via dimethylcelecoxib-mediated blocking of the transcription factors 
early growth response protein 1 (EGR1) and nuclear factor kappa-light-chain-enhancer of 
activated B cells (NF-кB) (313). This explains the increase in potency in intact cells 
compared to recombinant activity assay. 
Multiple dual mPGES-1 and 5-LO inhibitors have been reported (314-327). Many of these 
displayed IC50 values around or below 1 µM in recombinant enzyme assay or cell-based 
assay, but most have not been tested in human whole blood or in vivo. One of the best 
characterized is YS-121, which inhibited PGE2 production in human whole blood (IC50 of 2 
µM). YS-121 (1.5 mg/kg) decreased PGE2, LTB4, and prostacyclin formation along with 
exudate volume and number of pouch cells in an air pouch model in rats (323). Moreover, 
natural compounds like curcumin (328) and arzanol (329) can inhibit mPGES-1, although 
these compounds have numerous other anti-inflammatory effects. One honorable mention is 
MK-886 (330) that is an early inhibitor with activity towards human and rat mPGES-1 (331), 
but it binds to several other enzymes such as 5-lipoxygenase activating protein (FLAP) and 
COX-1 (332). FLAP and mPGES-1 belong to the membrane-associated proteins in 
eicosanoid and glutathione metabolism (MAPEG) enzyme family. They have similar 
structure and it is likely that an inhibitor towards one enzyme may also inhibit the other 
enzyme.  
The research approach used by Merck in the characterization of MF63 and its derivatives 
(294, 295) is the key methodology in the development of mPGES-1 inhibitors. These papers 
also highlighted two main hurdles. First, seemingly potent inhibitors towards recombinant 
mPGES-1 can display great loss in potency in human whole blood and low bioavailability in 
vivo. The second hurdle is that inhibitors designed for human mPGES-1 typically lacks or 
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have heavily decreased potency towards mouse and rat enzymes. Structure-activity 
relationship (SAR) studies have identified key amino acids in the inhibition of human 
mPGES-1 (333, 334), and these are not conserved in mouse or rat enzymes. Mapping of 
MF63 and other mPGES-1 inhibitors’ binding sites using hydrogen/deuterium exchange 
mass spectrometry revealed binding to the active site of mPGES-1 (335). Recently, 
crystallization of human mPGES-1 in complex with four inhibitors (including MF63) was 
published (336). The inhibitors showed a general binding mode with critical interactions with 
amino acid residues that are not conserved between human and rat/mouse mPGES-1.  
As presented, there are a limited number of studies with selective mPGES-1 inhibitors in 
relevant disease models in vivo. The results are promising (Table 2), but there is a demand 
for further studies with potent mPGES-1 inhibitors that lacks interspecies differences to study 
efficacy and safety in preclinical settings. 
1.5.4 Clinical use of mPGES-1 inhibitors 
The development of mPGES-1 inhibitors for clinical practice have been halted due to at least 
three reasons. First, as already mentioned, there is sufficient interspecies difference in the 
structure between human and rodent mPGES-1 that makes it challenging to develop a potent 
inhibitor that function in both preclinical and clinical models. Second, there is a guilt-by-
association to target the prostanoid pathway as all NSAIDs have boxed warning and should 
be used with care. This risk is too large for major pharmaceutical companies to take as it is 
of outmost importance that mPGES-1 inhibitors are safe in cardiovascular aspects. Third, it 
is unclear which disease(s) or disease event(s) that would be the primary target. NSAIDs are 
successfully used during a limited time to treat pain and inflammation, which means the 
increased risk for cardiovascular event is rather small. One might argue that this in turn means 
that there is no great need for a safer compound targeting the same pathway. However, the 
small increased risk in cardiovascular events makes a large difference as NSAIDs are used 
on a population scale. In addition, as mentioned earlier, the many adverse effects limit the 
use of NSAIDs for long-term therapy. It is possible that inhibition of mPGES-1 would be a 
better strategy for long-term treatment of inflammation and pain in rheumatic diseases or as 
long-term adjuvant therapy for cancer. The primary use of mPGES-1 inhibitors remains to 
be elucidated, where compounds should be tested in various Phase II clinical trials to unravel 
both their efficacy in treating various diseases and potential side effects. 
Based on the aforementioned research it becomes reasonable to suggest that targeting mPGES-
1 over COX-1/2 is a better therapeutic strategy. Multiple reviews support this conclusion (116, 
337-344). Nevertheless, there is no approved mPGES-1 inhibitor for clinical use. Up until 
2015, two compounds have reached Phase I clinical trials (www.clinicaltrials.gov), namely 
GRC 27864 (ID: NCT02179645 and NCT02361034, Glenmark Pharmaceuticals Ltd. India) 
and LY3023703 (ID: NCT01632579, NCT01849055, and NCT01872910, Eli Lilly and 
Company). There is still a need for additional research using preclinical models of 
inflammation and cancer to demonstrate that mPGES-1 inhibitors will replicate findings 
observed with genetic deletion of mPGES-1. Such studies using potent inhibitors will add much 
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needed proof-of-principles to boost the drug development. Absolute quantification of PGE2 
and other prostanoids is vital in these type of studies to confirm drug efficacy and to observe 
potential redirection of PGH2. 
Inhibitor (year) Species 
activity 
Recombinant 
mPGES-1 (IC50) 
Human whole 
blood (IC50) 
Results from in vivo 
models 
Ref. 
MK-886 (2001) Human, 
murine 
1.6-2.0 µM (human), 
3.2 µM (rat) 
~30 µM Not tested (225, 
293, 
326) 
23 and 30 
(2005) 
Human* 0.003 µM and 0.007 
µM 
Not active Not tested (293) 
MF63 (2006) Human 0.001 µM (human), 
>30 µM (mouse/rat) 
1.3 µM Analgesic, anti-pyretic 
(guinea pig); analgesic 
(knock-in mice) 
(294, 
295) 
26 and 44 
(2009) 
Human* 0.001 µM 0.20 µM and 
0.14 µM 
Analgesic (guinea pig) (296) 
AF3442 (2010) Human* 0.06 µM 29 µM Not tested (297) 
PF-9184 (2010) Human 0.017 µM (human), 
1080 µM (rat) 
5 µM Not active in air pouch 
model (rat) 
(299) 
YS-121 (2010) Human* 
(dual 
mPGES-1 
and 5-LO) 
3.4 µM 2 µM Decreased exudate 
volume and 
inflammatory cells (air 
pouch, rats) 
(323) 
AF3485 (2012) Human 2.6 µM Not tested Anti-angiogenic, anti-
proliferative (mice 
xenografts) 
(302) 
FR20 (2012) Human. 
murine 
0.13 µM (human), 
9 µM (mouse) # 
>100 µM Not tested (303) 
PF-4693627 
(2013) 
Human* 0.003 µM 0.109 µM Decreased PGE2 (air 
pouch, guinea pig) 
(304) 
Compound 28 
(2013) 
Human, 
murine 
13.8 µM (human), 
~5 µM (mouse) # 
>100 µM Not tested (309) 
Compound II 
(2013) 
Human, 
murine 
1.8 µM (human), 
0.62 µM (rat) 
Not tested Decreased PGE2 (air 
pouch, rat), decreased 
paw swelling (rat) 
(310) 
CIII (2013) Human, 
murine 
0.09 µM (human), 
0.9 µM (rat) 
~10 µM Decreased PGE2 and 
cells (air pouch, rat) 
(262) 
Compound 48 
(2015) 
Human* 0.005 µM 0.376 µM Not tested (311) 
Table 2. Summary of selected mPGES-1 inhibitors reported up until 2015. *Inhibition towards other 
species was not tested. #Broken cell assay of human HeLa or mouse RAW 264.7 cells.   
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2 AIM 
This PhD thesis aims to improve understanding about mPGES-1 and its inhibition in 
inflammation and cancer. The results will expand our knowledge of PGE2 and mPGES-1 
inhibitors in translational pharmacology. The objectives are: 
Paper I. To investigate prostaglandins as inflammatory mediators in human tendon disease.  
Paper II. To investigate differences in protein and lipid profiles after inhibition of mPGES-
1 versus COX-2 in vitro.  
Paper III. To demonstrate that inhibition of mPGES-1 is a potential therapeutic strategy in 
treating neuroblastoma in vivo.  
Paper IV. To characterize five new mPGES-1 inhibitors in preclinical models of 
inflammation and vessel tone.  
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3 RESEARCH APPROACH  
An essential part of eicosanoid research is the need to identify and quantify lipid mediators. 
The principal method for this, and used throughout this thesis, is liquid chromatography tandem 
mass spectrometry (LC-MS/MS). The Research approach section includes an introduction to 
LC-MS/MS, a presentation of prostanoid profiling, selected protocols used by the author, data 
presentation and statistical analyses, and ethical approval. Additional methods applied by the 
author, such as cell culture experiments and phospholipid profiling, or methods applied by co-
authors of the studies, such as animal experiments and flowcytometry analyses, are described 
in the papers included in this thesis. 
3.1 AN INTRODUCTION TO LC-MS/MS 
This section is dedicated to future students that are about to start their research journey using 
mass spectrometry. 
LC-MS/MS methodology is extremely diverse in terms of what to analyze and how to 
analyze. For this reason, the general methodology will be presented and the illustrations will 
be based on prostanoid analysis. A detailed introduction to the molecular theories and 
instrumentation of mass spectrometry is not covered and curious readers are referred to 
excellent textbooks (e.g. Mass spectrometry by Jürgen H. Gross, Springer, 2011).  
Mass spectrometry is a highly complex and versatile technique. In the most comprehensive 
sense, a mass spectrometer is a very accurate and sensitive scale. For many people, however, 
it is literally just a black box. Operating this sensitive scale typically requires a skilled 
analytical chemist that has the option to ask two fundamentally different but equally 
important research questions. The first one is: What does my sample contain? We call this 
type of analysis untargeted. The answer to this question will always be biased, as samples 
are typically processed prior to the analysis and there is always a detection limit to what a 
mass spectrometer can pick up as a signal. The second question is: How much of molecule 
X does my sample contain? This requires that the molecular weight (mass-to-charge ratio, 
m/z) and preferentially the fragmentation pattern (mass spectrum) of molecule X is known 
prior to the analysis. The mass spectrometer is optimized to specifically analyze molecule X 
and we therefore call this type of analysis targeted. The problem with the detection limit is 
still apparent in this type of analysis, but typically less of a problem as the mass spectrometer 
is set to exclusively look for the molecule(s) of interest. This means that we are more certain 
in finding what we look for but we have no idea what other molecules the sample might 
contain. In the first scenario (untargeted analysis), the analyte list is generated after the 
analysis while in the second scenario (targeted analysis), the analyte list is generated before 
the analysis. Modern mass spectrometers are able to answer both of these questions at the 
same time, although there is a trade-off in the amount of molecules that can be detected and 
at what concentration. This depends on the acquisition speed, which is how long time the 
instrument needs to spend to collect ions that results in a quantitative signal, and the dynamic 
range, which is the detection range of the smallest to the largest detected signal. 
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One can appreciate that determining what a sample contain and/or how much of something 
a sample contains is useful in multiple disciplines ranging from characterizing protein 
structures and identifying drugs to discovering biomarkers in clinical samples and 
quantifying pesticides in water. A mass spectrometer on its own is a very powerful tool and 
it is even more powerful when coupled to an LC system.  
3.1.1 Separation in the LC instrument 
The LC system enables separation of analytes before the mass spectrometer. A liquid sample 
is injected onto an analytical column that is chosen to retain molecules of interest. The 
column is composed of porous beads that will differ in material, diameter, and pore size. In 
addition, the column itself will differ in length and diameter. The column is the stationary 
phase and the liquid that flows through the column is the mobile phase. Several chemical or 
physical parameters are available to vary for the column, depending on the nature of the 
molecules of interest. Analytes can be separated based on polarity, size, or charge. We 
separate prostanoids (and other lipids) based on polarity where the column is relatively 
hydrophobic and contains beads with tails of 18 carbons in a row (C18 column). This is called 
reversed-phase chromatography, when the stationary phase is hydrophobic. Normal-phase 
chromatography is when the stationary phase is hydrophilic.  
Prostanoids are injected onto the column in a mobile phase that is relatively polar (80% water, 
20% acetonitrile). The mobile phase is acidic (0.05% formic acid, pH 3.0) to protonate the 
carboxylic group on prostanoids (pKa ~4.5), making the analytes less polar. This means that 
the prostanoids are retained on the column. Separation and elution are achieved by gradually 
increasing the organic proportion of the mobile phase (by going from 20% to 95% 
acetonitrile). The analytes will elute in the order of increasing hydrophobicity. This is 
dependent on which phase a molecule preferentially interact with. In other words, there is 
always an equilibrium in the interaction between the stationary phase and the mobile phase, 
and the equilibrium is pushed depending on the polarity of the mobile phase. A molecule will 
be retained in the stationary phase as long as the mobile phase is more polar than the 
stationary phase (the opposite is true when running in normal-phase). The analytes are 
separated in time and we say that they have different retention time.  
The retention time is dependent on the nature of the column, the gradient, and the 
composition of the mobile phase compared to the analyte of interest. In addition, the 
temperature and the flow rate will influence the separation. Temperature (thermal energy) 
affects the viscosity of liquids and thereby the diffusion coefficient between mobile and 
stationary phases. Increasing the temperature (40-50 °C) increases the column efficiency. 
Operating at a constant temperature (>25 °C) also leads to stable retention times since the 
effect of local room temperature fluctuations are removed. Higher temperature reduces the 
backpressure in the column, which enables higher flow rates, sharper peaks, reduced 
retention times, and shorter gradients. The concerns with increased temperature is that the 
column lifetime may be reduced, the molecule(s) of interest may not be thermally stable, and 
the peaks may be too narrow to enable quantification in the mass spectrometer. 
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The mobile phase can be designed with endless possibilities as one can elaborate with type 
of solvents, additives (salt), pH, and the gradient itself. Varying these parameters changes the 
peak shapes, the peak order, and the time between peaks (the resolution). There are two prime 
goals with separating analytes in the LC: it reduces the sample complexity prior to the mass 
spectrometer and it enables identification of analytes based on their retention time. 
3.1.2 Detection in the mass spectrometer 
All mass spectrometers operate based on three distinct features: ionization, separation, and 
detection. Molecules can be ionized in multiple ways, where electrospray ionization (ESI) is 
one commonly used strategy. ESI was first reported in 1984, and John B. Fenn and Koichi 
Tanaka jointly received half the Nobel Prize in Chemistry in 2002 for the analysis of 
biological macromolecules using mass spectrometry (the other half of the Nobel Prize was 
awarded to Kurt Wüthrich for his work on determining 3D structures of biological 
macromolecules using magnetic resonance spectroscopy). 
The constant flow of liquid from the LC system passes through a thin needle and is sprayed 
in small droplets. The fine spray occurs in the ion source where the droplets are quickly 
evaporated and ions are formed as the chamber is kept at high temperature and there is a high 
voltage applied between the needle and the source cone (interface to the mass spectrometer). 
The exact mechanism of ionization is beyond this thesis. We are satisfied with ions being 
formed in the aerosol under the influence of high voltage and the solvent is evaporated, 
generating ions in gas phase that are attracted into the mass spectrometer. Neutral molecules 
are mainly lost due to that these are not affected by electric (magnetic) fields. The ion spray 
is perpendicular to the source cone to avoid that neutral molecules will enter the mass 
spectrometer. The analytes flying in a mass spectrometer are therefore ions and which ions 
to analyze is selected by choosing the current direction. Positive ions are analyzed in positive 
mode (ES+) and negative ions are analyzed in negative mode (ES-).  
Ions pass through the source cone and via a hexapole (six metal rods to focus the ion beam) 
into the mass spectrometer, in this case a triple quadrupole detector (TQD). This is where the 
next separation happens. A TQD consists of three quadrupoles in a row followed by a detector. 
A quadrupole is composed of four metal rods, creating a path for the ions in the middle along 
the rods. Currents flow through the rods. By changing both the direction and the amplitude of 
the currents, selection of ions is enabled due to the change in the magnetic field in the 
quadrupole. A direct current (DC) voltage and a radio frequency (RF) voltage are applied. The 
selection of ions is based on that only ions that have a stable trajectory (movement) through the 
quadrupole can pass. Unstable ions will collide with the rods. The alternated RF will mainly 
affect smaller m/z as these are more sensitive (change trajectory quicker) than larger m/z. This 
means the RF enable discrimination of smaller m/z from medium or larger m/z. The DC will 
mainly affect larger m/z. In other words, the low mass cutoff is dependent on the RF and the 
high mass cut off is dependent on the DC. By increasing the DC and RF linearly, different m/z 
will be filtered out. Only ions that are large enough to constantly be refocused (or saved) by 
the RF will pass through. Ion size in terms of m/z is of course a relative concept. The key 
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concept is that a quadrupole is not performing one positive selection but two negative 
selections. Wolfgang Paul was awarded the Nobel Prize in Physics in 1989 for his work on 
quadrupoles and how to trap ions.  
As the currents are changing in the first quadrupole (Q1), certain ions will pass through. The 
second quadrupole (Q2) uses only RF current and this is where the fragmentation takes place. 
Ions are fragmented by collision-induced dissociation that occurs in a flow of gas (Ar, He, or 
N2). The fragmentation is not random and is influenced by the voltage (energy) applied. Each 
analyte of interest will fragment differently at different voltages, and just the right amount 
needs to be tested. Fragments then enter the third quadrupole (Q3) that operates just like the 
first: it will filter out ions. The combined selection of m/z in the first and third quadrupoles is 
called a transition. A TQD will typically cycle over a defined set of transitions, which is called 
multiple reaction monitoring (MRM). The selected ions (one species, one transition) hit the 
detector, generating a signal. It should be noted that a TQD can operate using other methods, 
including product ion scanning, precursor ion scanning, and neutral loss scanning. This is 
defined by whether Q1 and Q3 will cycle over defined transitions or scan over an interval of 
m/z. In product ion scanning, the Q1 is fixed at certain m/z while the Q3 scans for generated 
fragments. The results generated translate into which product ions a certain precursor is 
fragmented into. Precursor ion scanning is the opposite, i.e. when Q1 is scanning and Q3 is 
fixed at certain m/z. This type of results can be used to identify from which precursor ion(s) 
certain product ions are generated. Neutral loss scanning is when both Q1 and Q3 are scanning, 
but Q3 is scanning at a defined offset in m/z compared to Q1. In addition, one can chose to use 
only Q1 with fixed m/z or scanning without fragmentation in Q2 and selection in Q3. 
3.1.3 The detector: What is a signal? 
The signal in a mass spectrometer corresponds to the amount of ions measured. Multiple 
types of detectors exist but they can be divided into two main groups depending on the 
detection method: destructive or non-destructive. The first one relies on ions hitting a detector 
(metal plate), creating an electric current as the ions are neutralized. The signal is typically 
amplified with the use of electron multiplier. In the second detection method, ion motion is 
recorded. Ions oscillate back and forth in a magnetic field between two metal plates, where 
the motion is dependent on the m/z. This is called image current detection. The ion identity 
(m/z) is related to the motion frequency and the ion counts is related to the motion intensity. 
The first detection method was used in this thesis for prostanoid profiling.  
In untargeted analysis, the currents generated in the detector is translated into mass spectra. 
A mass spectrum is a plot with m/z on the x-axis and signal intensity on the y-axis. Mass 
spectra can be collected before or after fragmentation, generating distinct information. The 
first dimension (MS1 spectrum) contains precursor ions. The second dimension (MS2 
spectrum) contains product ions. When an instrument scan over a defined m/z range, mass 
spectra are collected at a certain speed and this will generate a large amount of data. Each 
mass spectrum can be used for identification and/or quantification, depending on the research 
question and experimental design. When running targeted analysis using a TQD, no mass 
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spectra are recorded as the instrument is only recording signals at predefined MRM 
transitions. 
As mentioned above, the nature of the signal is different depending on the mass analyzer 
method used. But what are the parameters influencing the signal intensity? This comes down 
to ionization efficiency and transmission efficiency. The ionization efficiency depends on the 
ionization method applied, the analyte of interest, and matrix effects. For example, molecular 
weight, volatility, charge, and polarity are molecular parameters that influence how efficient 
a molecule ionizes. Matrix effects is the presence of co-eluting molecules from the column 
that cause interferences with the ionization in the ion source. Although the voltage is high to 
ensure ionization of eluting molecules of interest, co-eluting molecules can compete for the 
available energy and/or modify droplet formation. The lower ionization efficiency caused by 
matrix effects can be reduced by considering the sample preparation (extraction, enrichment, 
and purification) and the separation on the column in the LC system. For example, the sample 
can be diluted prior to analysis, lower sample volume can be injected, or the flow rate and 
gradient can be altered. Transmission efficiency is the fraction of ions X generating a signal 
compared to the total amount of ions X generated in the ion source. This is dependent on the 
nature of the analyte (how stable the ion species is and how well it fragments) and the 
hardware of the instrument (how efficient the lenses and quadrupoles are in focusing and 
maintaining the ion beam).   
The absolute signal intensity is important, but it is a difficult term to relate to given the many 
parameters influencing the signal. Instead, signal-to-noise (S/N) is used to describe the 
certainty of the signal in a quantitative way. This is simply a relative term of how much 
stronger the intensity of a peak is compared to the background (noise) signal. Noise comes 
from many sources and can be electronic or chemical. There will always be noise in a mass 
spectrometer but there are different ways to increase the S/N. For example, increasing the 
acquisition time and increasing the number of spectra that are averaged. Targeted analysis 
typically has higher S/N as the mass spectrometer cycles through a defined set of transitions. 
Using a TQD, the time spent on each transition is longer than if the instrument would scan 
over a wide range of m/z. Another important parameter is the selectivity. The selection in the 
two quadrupoles enables confirmation in identity and improves S/N, as fewer possible 
molecules exist that has the same precursor and product ion compared to only the same 
precursor m/z.  
The S/N is what determines the limit of detection (LOD) and the limit of quantification 
(LOQ). There is no exact definition but typically a signal is detected if S/N > 3 and quantified 
if S/N > 10. These are guidelines to have a cut-off for a positive signal. It should be noted 
that the certainty in quantification is not improved by increasing the certainty in 
identification, i.e. by confirming a peak via multiple MRM. Certainty in quantification and 
identification are different entities, and quantification under S/N > 10 should be avoided. 
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3.1.4 MRM method development 
There are several parameters to consider when introducing an analyte into your LC-MS/MS 
platform. First of all, one needs to guess (or test) if the analyte will ionize and “fly” better in 
positive or negative mode. An analyte can be measured or fly with similar performance in both 
modes. The actual m/z is determined in the first step. It is not crucial that the m/z is in perfect 
agreement with the nominal mass, since every TQD will have minor differences effecting the 
observed m/z. Given that the instrument is calibrated, the observed m/z will not differ more 
than fractions of Da from the nominal value. The observed m/z can be obtained by performing 
a narrow scan, about ±4 Da from the molecular mass. The instrument then cycles over the 
defined range, resulting in a signal that is plotted against time in a total ion chromatogram 
(TIC). Within the TIC, a peak distribution of m/z values is obtained. The next step is to optimize 
the cone voltage. The high capillary voltage for ionization is preset depending on ES+ (e.g. 3 
kV) or ES- (e.g. 2.7 kV) while the cone voltage (e.g. 10-100 V) is altered to extract ions of 
interest into the mass spectrometer. Finding the optimal cone voltage is tested by varying it 
within an injection or by injecting the analyte of interest in a sequence with different cone 
voltages for each injection. Fragmentation is the next step to test. This is performed by fixed 
m/z in Q1, applying energy (e.g. 20 V) in the Q2, and scan over a range (m/z 100-360, if the 
analyte of interest is m/z 350 and adduct ions are not of interest) in Q3. This will generate mass 
spectra covering m/z 100-360. If fragments are not observed, higher voltage can be applied. 
After this, one or several fragments are selected and the collision energy is noted or further 
optimized for. This is performed at fixed values in the Q1 and Q3, resulting in a transition, and 
varying the collision energy in Q2.    
3.1.5 Pros and cons with LC-MS/MS 
It is now clear that the many parameters and settings used within LC-MS/MS makes it a 
complex and flexible technique. Almost any molecule of interests can be measured in any 
type of sample matrix – at least in theory. LC-MS/MS is often the method of choice for the 
great selectivity, enabling certainty in the identification of the measurements. This is the main 
advantage over antibody-based methods, such as enzyme-linked immunosorbent assay 
(ELISA), which are dependent on the antibody specificity. In addition, LC-MS/MS can 
generate in-depth data in terms of structure, identity, and molecular modifications that is very 
difficult to observe or distinguish using ELISA. Both LC-MS/MS and ELISA can be used 
for multiplexing, which is to analyze multiple molecules of interest at the same time within 
the same injection/sample. However, ELISA has the advantage over LC-MS/MS in many 
applications as it is easy to use, cheaper, typically requires less sample preparation, shorter 
time-to-results, higher throughput, and can have a very low LOQ. Compared to gas 
chromatography (GC), LC can be used for any soluble analyte while GC requires volatile 
analytes. LC is therefore preferred when working with biological matrices with relatively 
hydrophilic analytes of interests. Separation in GC is typically quicker due to the increased 
movement of molecules in gas phase compared to liquid phase, which can enable more 
narrow peaks and shorter run times. Analytes that are less volatile can be derivatized by 
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coupling of a functional group, although the resulting molecule still needs to be thermally 
stable as GC operates at higher temperature than LC. Although derivatization can be time-
consuming and costly, it may enable quantification of otherwise undetectable analytes.  
3.2 PROSTANOID PROFILING 
Prostanoids, or any eicosanoid, are typically produced at low picomolar to nanomolar 
concentrations in highly complex biological matrices. This makes them challenging to 
quantify. There are also multiple lipids, or biomolecules in general, that have the exact same 
molecular weight and very similar structures. This places a high demand on the selectivity in 
the analysis to ensure correct identification. This section will introduce the reader to sample 
preparation and the LC-MS/MS workflow used for prostanoid profiling. 
The sample complexity needs to be reduced and the prostanoid content needs to be enriched. 
This is performed by extraction. Liquid-liquid extraction is the use of two solvents with 
different polarity. For example, prostanoids can be extracted from cell culture supernatant (or 
tissue homogenate) with ethyl acetate. Another option is to use solid-phase extraction (SPE). 
This is based on capturing of analytes in a column followed by washing of the matrix and 
elution of the analytes. Prostanoids are fatty acid derivatives with a carboxylic group that is 
protonated at low pH. The use of a SPE column containing long-chain carbon (C18), which is 
fairly hydrophobic, will retain protonated prostanoids that can be eluted in MeOH that is easily 
evaporated. Despite the selection of extraction method, it is vital to spike each sample with an 
internal standard mix. In the best case, the mix should contain 13C isotope-labeled variants of 
each analyte of interest. The second best option is deuterated variants. The internal standard 
will compensate for storage effects, extraction recovery during sample preparation, and matrix 
effects in the mass spectrometer if added early in the sample preparation. However, the internal 
standard does not overcome loss in sensitivity due to poor extraction efficacy and/or interfering 
matrix effects. In other words, using an internal standard does not improve the LOQ but rather 
compensates for differences in extraction recovery and matrix effects between samples. The 
deuterated variant have almost identical chemical properties as the non-deuterated molecule. It 
will therefore be extracted at the same efficacy and elute at approximately the same retention 
time as the endogenous molecule. This helps confirming the identity of the endogenous 
prostanoid in the sample. 
Prostanoids are quantified in absolute concentration. This is done by internal standard 
normalization and quantification to an external standard curve. Ideally, the standard curve 
should be prepared in the same type of matrix as the samples to replicate the loss in signal due 
to extraction recovery and/or matrix effects. This is difficult when the sample matrix is tissue 
homogenate or when all the matrices (samples) are positive for the analytes of interest. The 
most important part with the standard curve is that it will give the dynamic range where the 
response vs. injected amount is linear, i.e. the response factor. The linearity is assumed to be 
the same for an analyte despite the sample matrix when using an internal standard, but the LOQ 
will be different depending on the sample matrix. This means that a standard curve in solution 
enables reliable quantification. The loss in recovery is estimated by spiking a sample before 
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and after the extraction and calculating the ratio. The interference of matrix effects during 
ionization in the ion source is estimated by comparing the signal in a spiked extracted sample 
with the signal in a solution blank sample. LOQ for each analyte is given by the lowest 
quantified standard with S/N > 10.  
Every extraction is evaluated by using technical blanks and double blanks. The technical blank 
is treated just like a sample but it does not contain the actual sample matrix, and this is a positive 
control for the sample preparation and to control for false positive signals (contamination) 
during the sample preparation. The double blank is treated like the blank but it lacks the internal 
standard. This is to evaluate that the internal standard gives a signal in the technical blank. The 
performance of the LC-MS/MS analysis is evaluated with a quality control (QC) sample, 
containing analytes of known concentrations. This will yield a response that can be recorded 
and compared to each previous analysis. In addition, the peak shape, the retention time, and the 
peak resolution is checked at this stage. The LOQ is evaluated with the standard curve, which 
is prepared fresh from a stored stock for each analysis. This is typically analyzed first and last 
in the analysis or in between long sample lists to observe loss in performance during the 
analysis. QC samples in solution or a pooled true sample are injected every 10-20th injection to 
observe changes in retention times or responses during the analysis. 
Prior to the analysis the sample cone (interface to the mass spectrometer) is cleaned, fresh 
solutions for mobile phases are prepared, the LC instrument is primed with solutions, the 
column is flushed and equilibrated, and the backpressure in the instrument is monitored. When 
ready, the samples are queued and the instrument will run the sequence. Hopefully the run will 
finish and the instrument goes into shutdown. However, multiple errors can arise: backpressure 
reaches instrumental limit due to injection of particles or build-up of unwanted material from 
the samples, leakage due to column or tube fittings, loss in signal due to accumulation of 
material on the needle in the electrospray, and (yes, this has happened!) loss of vacuum due to 
turbo pump failure. 
The extraction takes 2-10 hrs, depending on how many samples and what type of samples. The 
extracted samples are then evaporated for at least 2 hrs. Starting the LC-MS/MS analysis takes 
2-4 hrs, depending on preparations. The actual analysis takes 15 min per sample for prostanoid 
profiling. A normal run with 20-100 samples plus QC samples, standard curve, and blank 
injections takes 10-30 hrs. Peak integration and data analysis takes at least 2 hrs. This means 
that the time-to-results is a minimum of two days but can be as long as one week. The 
throughput is about 200 samples per week, if samples are extracted in 2x96-well plates at the 
same time. However, this is when everything already is optimized and standardized for (and 
no errors occur). 
The LC-MS/MS method used in this thesis is specifically developed and optimized for to cover 
the main prostanoids, as the research questions and disease models used throughout the 
different studies involved prostanoids. However, the LC-MS/MS method contains a broad 
spectrum of eicosanoids including 6-keto PGF1α, PGE3, TXB2, PGF2α, PGE2, PGD2, LTB4, 
RvD1, RvD2, 5-HETE, 12-HETE, 15-HETE, 13-hydroxyoctadecadienoic acid (13-HODE), 
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15d-PGJ2, protectin DX, and 17-hydroxy-decosahexaenoic acid (17-hydroxy DHA) (Table 3). 
These lipids were individually optimized for in the mass spectrometer and the recovery 
efficiency during extraction have been evaluated. Nevertheless, analytical performance of all 
eicosanoid classes where not controlled for with deuterated internal standards to account for 
extraction recovery and matrix effects in each specific biological sample. Eicosanoids are 
chemically diverse molecules and there is no one-size-fits-all regarding the extraction 
procedure. In addition, eicosanoids are likely to have different stability at different conditions 
affected by temperature, light, oxygen, and pH. This means that the only correct procedure to 
report absolute concentrations of eicosanoids is to spike samples with deuterated (or 13C 
isotope-labeled) internal standards for each analyte of interest, as mentioned earlier. This of 
course comes with a price tag and increases the number of MRM transitions. In addition, this 
will require additional time if multiple extraction protocols and/or gradients are used. 
Different LC-MS/MS based methods can be deployed to specifically investigate other classes 
of eicosanoids. However, many of these lipids are found in extremely small quantities, placing 
a large demand on the instrumental set up. As discussed above, several instrumental parameters 
will affect the signal in the mass spectrometer. The instrumental set-up used throughout this 
thesis is not able to deliver better performance in terms of analytical sensitivity. It must be 
acknowledged that there are lower LOQ for eicosanoid analyses reported in the literature (345-
349), and that analyses can be performed with lower sample amount and in shorter gradients. 
Nevertheless, it is unclear in some studies if the reported LOQ is the concentrations measured 
of spiked standard in un-extracted solution or concentration measured of spiked standard in 
(extracted) biological sample. The lack of deuterated standards, the reported low pg/mL in 
complex biological matrices, and the cutoff of S/N > 3 or 5 for quantification of peaks place a 
question mark behind the endogenous presence of some lipids. PGE2 is the product of mPGES-
1 during inflammation and cancer, and it is reasonable to include at least the main prostanoids 
in any type of research regarding COX or mPGES-1 and their inhibition. This is to observe any 
shunting or perturbation in the prostanoid profile.  
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Analyte Item No.* 
Retention 
time (min) 
Precursor 
(m/z) 
Fragment 
(m/z) 
Cone 
voltage (V) 
Collision 
energy (V) 
6-keto PGF1α 15210 3.2 369.1 245.2 53 21 
6-keto PGF1α-d4 315210 3.2 373.1 249.2 53 21 
CIII (1st ion) 
N/A 
4.5 383.6 174.1 55 50 
CIII (2nd ion) 4.5 383.6 309.3 55 35 
PGE3 14990 4.7 349.1 269.3 45 20 
TXB2 19030 5.0 369.2 169.2 30 20 
TXB2-d4 319030 5.0 373.2 173.2 30 20 
PGF2α 16010 5.7 353.3 309.3 45 23 
PGF2α-d4 316010 5.7 357.3 313.3 45 23 
PGE2 (1st ion) 
14010 
6.0 351.1 271.3 38 19 
PGE2 (2nd ion) 6.0 351.1 315.4 38 14 
PGE2-d4 314010 6.0 355.1 275.3 38 19 
PGD2 12020 6.2 351.1 271.3 38 19 
PGD2-d4 312020 6.2 355.1 275.3 38 19 
RvD2 10007279 6.4 375.5 175.2 35 30 
RvD1 10012554 7.0 375.5 141.0 30 20 
LTD4-d5 10006199 8.1 500.3 177.2 40 31 
LTC4-d5 10006198 8.2 629.4 272.2 50 31 
Protectin DX 10008128 8.4 359.3 153.1 33 19 
LTB4 20110 8.5 335.3 195.2 40 17 
LTB4-d4 320110 8.5 339.3 197.2 40 17 
15d-PGJ2 18570 8.8 315.2 271.2 17 24 
15d-PGJ2-d4 318570 8.8 319.2 275.2 17 24 
13-HODE 38600 8.9 295.4 195.3 40 20 
15-HETE 34720 8.9 319.4 219.1 30 15 
15-HETE-d8 334720 8.9 327.4 226.2 30 15 
17(S)-HDoHE 10009794 9.0 343.3 201.2 30 16 
12-HETE 34570 9.0 319.4 179.1 35 17 
12-HETE-d8 334570 9.0 327.4 184.1 35 17 
5-HETE 34230 9.1 319.4 115.0 30 18 
5-HETE-d8 334230 9.1 327.4 116.0 30 18 
Table 3. Experimental details for quantification of eicosanoids and CIII by LC-MS/MS. *Cayman 
Chemical. 
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3.3 PROTOCOLS 
3.3.1 Whole blood assay 
Preparation: Inhibitors were reconstituted at 10 mM in DMSO (D2250-100ML, Sigma-
Aldrich), aliquoted in Eppendorf tubes or 96-well plates, and stored at -20 or -80 °C. A fresh 
aliquot was used at each experiment. LPS (L6529-1MG, Sigma-Aldrich) was reconstituted in 
PBS (D8537-500ML, Sigma-Aldrich) to a final concentration of 0.25 mg/mL and kept at +8 
°C. 
The assay: Inhibitors, positive controls (diclofenac and NS-398), and vehicle control (DMSO) 
were prepared in PBS at room temperature (RT) with no direct light on. The treatments were 
prepared in 25 µL portions to a U-shaped 96-well plate and 200 µL of freshly drawn heparin 
blood (<2 hrs stored at RT) was added to the plate. The plate was incubated at 37 °C for 30 
min and then 25 µL of 0.1 mg/mL LPS in PBS was added followed by pipetting up and down 
3 times (final concentration of LPS was 10 µg/mL). The plate was incubated for 24 hrs at 37 
°C and then centrifuged at 3000 g for 10 min at 4 °C. Working on ice, 100 µL plasma was 
recovered to a new plate, sealed with aluminum foil, and stored at -80 °C. 
3.3.2 Extraction of prostanoids 
0. Preparations: Organic solutions (MeOH, MeCN, EtOH) were of LC-MS grade. Only fresh, 
highly pure water was used (18.2 MΩ at 25 °C, ppb TOC < 3.0). Solutions for extraction were 
prepared fresh daily. The pH was checked when applicable (0.05 % formic acid solution, pH < 
2.0). The internal standard mix contained 340 ng/mL 6-keto PGF1α-d4 (#315210), 160 ng/mL 
PGF2α-d4 (#316010), 240 ng/mL PGE2-d4 (#314010), 160 ng/mL PGD2-d4 (#312020), 160 
ng/mL TXB2-d4 (#319030), and 160 ng/mL 15d-PGJ2-d4 (#318570) prepared in 100% MeOH 
and stored at -20 °C. The standard curve contained 11 stock solutions with 24 to 0.023 pmol/µL 
of 6-keto PGF1α (#15210), PGF2α (#16010), PGE3 (#14990), PGE2 (#14010), PGD2 (#12020), 
TXB2 (#19030), and 15d-PGJ2- (#18570) prepared in 100% EtOH and stored at -80 °C. All 
prostanoid standards were from Cayman Chemical. 
1a. Cell supernatant samples: Cell supernatants (400-1000 µL) were thawed on ice, diluted 
with water to 1 mL, and spiked with 50 µL deuterated internal standard mix (above). The 
samples were acidified with addition of 0.5-2 µL 100% formic acid (pH < 4.0) and left to 
equilibrate on shaker for 30 min on ice prior to extraction using solid-phase extraction (SPE). 
1b. Plasma samples: Plasma samples (100 µL) were thawed on ice and spiked with 50 µL 
deuterated internal standard mix (above). Protein precipitation was performed by addition of 
800 µL 100% MeOH, vortexing, and centrifugation at 3000 g for 10 min at 4 °C. The 
supernatants were collected in a new plate and evaporated under vacuum for 4 hrs, until 100-
200 µL remained. These were then diluted to 1 mL with 0.05% formic acid in water and 
subjected to SPE. 
1c. Tissue samples: Frozen tissues (tumor, spleen, brain) were used as whole or pieces were 
excised and weighed (50-500 mg). Tissues were kept on dry ice and spiked with 100 µL 
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deuterated internal standard mix (above). Additional MeOH was added (500-1000 µL). 
Homogenization was performed using a pellet pestle (art# 749515-1500, Kontes) for 1-2 min 
or a tip-sonicator (Sonoplus, Bandelid) 2-4 times 30 sec at 35% power. Homogenates were 
incubated at -20 °C for 30 min and then centrifuged at 20.000 g for 10 min at 4 °C. The 
supernatants were collected and extraction was repeated once by addition of 500 µL of 100% 
MeOH, vortex for 30 sec, centrifugation at 20.000 g for 10 min at 4 °C, and collection of 
supernatant. Pooled supernatants were evaporated for 4 hrs until 100-200 µL remained. These 
were diluted to 1 mL with 0.05% formic acid in water and subjected to SPE. 
2. SPE: Acidified samples (about 1 mL) were loaded onto Oasis HLB 1cc 30mg single-use 
column or 96-well plate (Waters Corporation) that had been pre-conditioned with 1 mL of 
100% MeOH and 1 mL of 0.05% formic acid in water. The column or plate was washed with 
10% MeOH, 0.05% formic acid in water and prostanoids were eluted with 100% MeOH. The 
eluates were dried under vacuum (at least 4 hrs, but typically over-night) and stored at -20 °C. 
3. LC-MS/MS analysis: Dried samples were reconstituted in 50 µL of 20% MeCN in water, 
vortexed (5-10 sec), allowed to dissolve at +8 °C (30 min), centrifuged at 20.000 g for 10 min 
at 4 °C (if plate: 3000 g, 10 min, 4 °C), and then transferred to vials or collection plate. 
Prostanoids were quantified in negative mode with MRM method, using a triple quadrupole 
mass spectrometer (Acquity TQ detector, Waters) equipped with an Acquity H-class UPLC 
(Waters). Separation was performed on a ACQUITY UPLC BEH C18, 130Å, 50 x 2.1 mm, 
1.7 µm column (Waters) with a 12 min stepwise linear gradient (20-95%) at a flowrate of 0.6 
mL/min with 0.05% FA in MeCN as mobile phase B and 0.05% FA in water as mobile phase 
A. The analytical column was equipped with a ACQUITY UPLC BEH C18 VanGuard, 130Å, 
1.7 µm, 5 mm x 2.1 mm pre-column (Waters). The samples were kept at 10 °C. The injection 
volume was 10 µL and the column was kept at 40 °C. The source temperature was 150 °C, 
desolvation temperature was 500 °C, cone gas flow was 50 L/h, and desolvation gas flow was 
1000 L/h.  
4. Data analysis: Data were analyzed using MassLynx software, version 4.1, with internal 
standard calibration and quantification to external standard curve. Only analytes with peaks 
intensities of signal-to-noise greater than 10 (S/N >10) were considered in our data analysis. 
The lower LOQ was typically 0.05 pmol (~20 pg) injected on column for the main prostanoids. 
This corresponds to quantification limit of 0.25 nM (~100 pg/mL) if extracting 1 mL of sample 
or 2.5 nM (~1000 pg/mL) if extracting 100 µL sample. 
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3.4 DATA PRESENTATION AND STATISTICAL ANALYSES 
Readers are referred to each paper and the Results section in this thesis for details regarding 
data presentation and statistical analyses. Statistical analyses were performed using Graphpad  
prism v. 5-7 (Graphpad Software Inc., USA). The level of significance was set to P < 0.05 if 
not stated otherwise. 
3.5 ETHICAL APPROVAL 
Paper I included collection of tendon biopsies of supraspinatus tendons, Achilles tendons, and 
hamstring tendons. Ethical approval for these procedures was granted with references 
14/SC/0222 (South Central Oxford B, UK), 14/NI/1063 (Northern Ireland Research Ethics 
Committee, UK), and 09/H606/11 (Oxford Musculoskeletal Biobank, UK). Full informed 
consent according to the Declaration of Helsinki was obtained from all patients. Paper II 
involved work on commercially available cancer cell line and no ethical approval was required 
for this work. Paper III included work on human tumors from neuroblastoma patients and two 
preclinical mouse models of neuroblastoma. Ethical approval and relevant informed consent 
was obtained according to the references 2009/1369-31/1 and 03/736 (Research Ethics 
Committee at Karolinska University Hospital, Sweden). Ethical approvals for mouse 
experiments were granted with references N231/14, N26/11, and N42/14 (Regional Ethics 
Committee on Animal Experiments, Sweden). Paper IV included work on human material, 
two preclinical rat models, and one preclinical mouse model. Ethical approval for collection of 
blood from healthy donors was granted by reference 02-196 (Research Ethics Committee at 
Karolinska University Hospital, Sweden). Ethical approval for collection of biopsies for ex vivo 
myography experiments was granted with reference 273/94 (Research Ethics Committee at 
Karolinska University Hospital, Sweden). Full informed consent according to the Declaration 
of Helsinki was obtained from all subjects. Ethical approval for air pouch experiments in mice 
was granted with reference N86/13 (Regional Ethics Committee on Animal Experiments, 
Sweden). Pharmacokinetics study in rats was approved by Cerep Institutional Animal care and 
Use Committee (IACUC), USA. Paw swelling study in rats was approved by Institutional 
Animal Ethics Committee of Anthem Biosciences, India. 
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4 RESULTS 
4.1 PROSTAGLANDINS AND MPGES-1 IN TENDINOPATHY 
We have investigated the role of prostaglandins in human tendon disease (Paper I). The results 
showed that tendon tissues from diseased supraspinatus and diseased Achilles expressed 
elevated levels of COX-2 and the two terminal synthases PGIS and mPGES-1 compared to 
healthy hamstring tendon tissue. We isolated cells from tendon biopsies and cultured them in 
vitro. These cells are termed tendon-derived stromal cells and they do not express markers for 
leukocytes (CD45) or endothelial cells (CD34). We found that cells from diseased shoulder 
and diseased Achilles tendons produced prostacyclin and PGE2 while cells from healthy 
hamstrings only produced PGE2. COX inhibitors naproxen and NS-398 terminated the 
prostaglandin production, while mPGES-1 inhibitor CIII reduced PGE2 and increased 
prostacyclin formation. In an attempt to study prostaglandin production in tendon disease in 
connection to pain, we used tendon biopsies from patients with resolved or persistent pain post-
surgical treatment and quantified mRNA levels of prostaglandin synthetic enzymes. We found 
increased expression of PTGIS in patients with resolved pain. 
We have also studied phospholipid profiles in tendon-derived cells by LC-MS/MS. This was 
performed on tendon cell pellets from in vitro experiments and we quantified 52 phospholipids 
in each sample: 7 lysophosphatidylethanolamines (LPEs), 9 lysophosphatidylcholines (LPCs), 
21 phosphatidylcholines (PCs), 6 phosphatidylcholine (PEs), and 9 sphingomyelins (SMs). 
Phospholipids are named based on head group with total number of carbons and total number 
of saturation in the two acyl chains. Relative changes in phospholipids upon treating cells with 
IL-1β was investigated. Six phospholipids were altered with IL-1β treatment despite disease 
state or anatomical location: LPE(20:5), LPC(14:0), LPC(20:5), and PC(30:0) where increased 
while PC(38:5) and PC(38:4) were decreased (Table 4). We next investigated if COX or 
mPGES-1 inhibition altered the IL-1β induced phospholipid profiles. This was performed on 
cells from diseased shoulder and healthy hamstring (Figure 4). Our results show that treatment 
with CIII reversed the effect observed with IL-1β on three lipids in cells from healthy 
hamstrings: LPE(16:0), LPE(20:4), and LPC(20:5). This was not observed with naproxen or 
NS-398. In cells from diseased supraspinatus, CIII decreased LPE(16:0) and increased 
PC(30:0). Our results show that IL-1β induced alterations in the cellular phospholipid profile 
and that inhibition of mPGES-1 or COX-1/2 affect the cellular lipid profile differently in 
tendon-derived cells.  
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Phospholipid 
Healthy hamstring 
(n=8) 
Diseased supraspinatus 
(n=8) 
Diseased Achilles 
(n=6) 
Ctrl IL-1β Ctrl IL-1β Ctrl IL-1β 
LPE(16:0) 5.8 ± 1.2 4.9 ± 1.2* 4.7 ± 1 3.9 ± 1.1* 7.2 ± 1.5 6.8 ± 1.2 
LPE(18:2) 2.0 ± 0.6 2.1 ± 0.6 2.0 ± 0.4 2.0 ± 0.4 0.7 ± 0.2 0.8 ± 0.2 
LPE(18:1) 18.6 ± 3.4 19.9 ± 3.5* 15.6 ± 2.9 16.6 ± 3.2 19.2 ± 3.2 20.1 ± 2.8 
LPE(18:0) 10.9 ± 2.3 9.9 ± 2.7 8.7 ± 2.6 6.6 ± 1.5* 16.0 ± 8.7 16.5 ± 5.4 
LPE(20:5) 2.6 ± 1.2 3.3 ± 1.3* 5.0 ± 3.2 5.9 ± 2.7* 2.2 ± 0.9 2.9 ± 1.1* 
LPE(20:4) 40.0 ± 5.7 39.6 ± 4.5 49.0 ± 5.6 49.3 ± 4.2 38.5 ± 8.1 37.3 ± 7.5 
LPE(22:6) 20.0 ± 5.2 20.3 ± 4.7 15.0 ± 2.4 15.7 ± 2 16.2 ± 4.9 15.6 ± 3.9 
LPC(14:0) 0.6 ± 0.3 1.0 ± 0.3* 0.5 ± 0.2 0.7 ± 0.2* 0.7 ± 0.1 0.9 ± 0.1* 
LPC(16:1) 1.7 ± 0.5 2.7 ± 0.6* 1.5 ± 0.5 2.4 ± 0.6* 2.1 ± 0.4 2.4 ± 0.4 
LPC(16:0) 51.9 ± 2.6 48.8 ± 4.9 50.8 ± 2.4 44.4 ± 8.6 32.2 ± 0.5 32.3 ± 1.6 
LPC(18:2) 3.7 ± 0.9 3.1 ± 0.4 3.6 ± 0.8 3.4 ± 0.6 0.9 ± 0.2 1.0 ± 0.3 
LPC(18:1) 9.7 ± 1.2 11.5 ± 2.3* 8.7 ± 0.7 11.2 ± 2.8* 16.4 ± 1.4 16.9 ± 2.1 
LPC(18:0) 29.6 ± 4.2 28.9 ± 4.0 31.0 ± 4.0 31.1 ± 4.8 44.4 ± 2.6 41.8 ± 2.7 
LPC(20:5) 0.2 ± 0.1 0.4 ± 0.2* 0.4 ± 0.3 0.8 ± 0.5* 0.2 ± 0.1 0.4 ± 0.2* 
LPC(20:4) 2.2 ± 0.5 3.1 ± 1.0 3.0 ± 0.9 5.1 ± 1.9* 2.6 ± 1.0 3.2 ± 1.1 
LPC(22:6) 0.4 ± 0.1 0.6 ± 0.2* 0.4 ± 0.1 0.9 ± 0.3* 0.7 ± 0.2 1.0 ± 0.5 
PC(28:0) 0.4 ± 0.2 0.5 ± 0.2* 0.3 ± 0.1 0.4 ± 0.3 0.3 ± 0.1 0.4 ± 0.1* 
PC(30:1) 9.1 ± 2.6 8.9 ± 2.4 10.7 ± 2.9 9.5 ± 2.3* 7.8 ± 0.7 7.9 ± 1.0 
PC(30:0) 4.4 ± 1.0 5.0 ± 0.9* 3.5 ± 0.5 4.1 ± 0.8* 3.2 ± 0.6 3.7 ± 0.4* 
PC(32:3) 0.2 ± 0.1 0.4 ± 0.2* 0.2 ± 0.1 0.3 ± 0.3 0.2 ± 0.1 0.2 ± 0.1 
PC(32:2) 2.7 ± 1.0 2.8 ± 1.1 1.9 ± 0.6 2.8 ± 2.2 1.3 ± 0.4 1.4 ± 0.6 
PC(32:1) 12.9 ± 2.3 15.6 ± 3.4* 12.1 ± 3.5 13.4 ± 3.6 11.3 ± 1.6 11.3 ± 1.5 
PC(32:0) 5.9 ± 2.1 7.2 ± 2.9 6.9 ± 1.8 8.1 ± 3.7 8.1 ± 1.6 9.1 ± 1.3* 
PC(34:4) 0.3 ± 0.1 0.3 ± 0.1 0.2 ± 0.1 0.3 ± 0.3 0.2 ± 0.04 0.2 ± 0.03 
PC(34:3) 2.0 ± 0.4 2.4 ± 0.8 1.6 ± 0.3 2.4 ± 1.6 0.8 ± 0.2 0.9 ± 0.2 
PC(34:2) 16.6 ± 4.1 15.0 ± 2.3 14.4 ± 1.4 15.6 ± 2.1 7.0 ± 1.2 6.7 ± 1.2 
PC(34:1) 20.2 ± 5.7 20.8 ± 4.9 21.4 ± 4.3 20.3 ± 6.3 21.6 ± 1.5 21.4 ± 0.7 
PC(34:0) 2.2 ± 0.6 2.3 ± 0.6 2.7 ± 0.6 2.2 ± 0.6 2.9 ± 0.3 3.0 ± 0.3 
PC(36:8) 0.8 ± 0.2 0.8 ± 0.2 0.9 ± 0.2 0.8 ± 0.2* 1.5 ± 0.1 1.6 ± 0.1 
PC(36:4) 4.6 ± 2.1 3.9 ± 1.1 4.6 ± 1.0 4.7 ± 0.7 3.6 ± 0.6 3.3 ± 0.6* 
PC(36:3) 4.2 ± 1.0 3.4 ± 1.2 4.1 ± 0.7 3.7 ± 0.9 2.8 ± 0.1 2.7 ± 0.1 
PC(36:2) 5.6 ± 1.9 3.7 ± 1.8 5.3 ± 1.4 3.8 ± 1.1* 8.5 ± 0.8 8.4 ± 0.7 
PC(36:1) 2.2 ± 1.0 2.3 ± 1.1 3.0 ± 1.0 2.5 ± 1.4 7.1 ± 0.9 7.3 ± 0.4 
PC(36:0) 0.5 ± 0.1 0.6 ± 0.2 0.7 ± 0.2 0.7 ± 0.1 1.0 ± 0.1 1.0 ± 0.1 
PC(38:6) 1.2 ± 0.5 1.0 ± 0.3 1.1 ± 0.2 1.1 ± 0.3 1.4 ± 0.2 1.4 ± 0.1 
PC(38:5) 2.0 ± 0.7 1.6 ± 0.4* 2.2 ± 0.5 1.8 ± 0.3* 4.5 ± 0.4 4.0 ± 0.4* 
PC(38:4) 1.8 ± 0.6 1.4 ± 0.4* 2.1 ± 0.7 1.6 ± 0.7* 4.9 ± 0.8 4.4 ± 1.0* 
PE(32:1) 9.0 ± 3.4 8.0 ± 2.3 7.0 ± 2.6 8.2 ± 5.1 4.9 ± 0.8 4.6 ± 1.0 
PE(34:2) 16.8 ± 6.6 17.7 ± 6.8 12.9 ± 3.4 15.2 ± 4.6* 8.2 ± 2.1 8.4 ± 1.8 
PE(34:1) 24.8 ± 5.6 24.6 ± 6.8 25.8 ± 6 24.8 ± 7 26.1 ± 4.3 29.5 ± 4.2 
PE(36:4) 7.8 ± 3.9 7.4 ± 2.2 7.8 ± 1.3 10.7 ± 4.5 6.3 ± 0.7 6.6 ± 1.1 
PE(36:2) 22.0 ± 8.7 21.4 ± 6.8 19.9 ± 5.9 18.1 ± 7.8 29.3 ± 1.7 28.6 ± 2.7 
PE(38:5) 19.6 ± 6.5 20.9 ± 7.1 26.6 ± 4.7 23.0 ± 4.8 25.3 ± 3.4 22.3 ± 2.4 
SM(32:1) 6.8 ± 2.2 5.4 ± 1.5 6.4 ± 1.9 6.6 ± 3.3 3.5 ± 0.4 3.4 ± 0.7 
SM(32:0) 1.0 ± 0.2 0.7 ± 0.1 0.7 ± 0.1 0.8 ± 0.4 0.4 ± 0.1 0.4 ± 0.1 
SM(34:2) 7.7 ± 3.4 6.3 ± 2.3 6.7 ± 2.6 7.0 ± 4.4 5.4 ± 1.7 6.2 ± 1.1 
SM(34:1) 52.8 ± 4.3 53.2 ± 5.6 57.9 ± 4.3 55.1 ± 9.4 58.1 ± 5.4 57.2 ± 6 
SM(34:0) 9.1 ± 2.4 8.5 ± 2.2 7.3 ± 0.7 7.2 ± 0.7 9.9 ± 0.5 9.8 ± 0.9 
SM(36:2) 1.6 ± 0.3 1.6 ± 0.3 1.6 ± 0.3 1.6 ± 0.3 1.5 ± 0.2 1.5 ± 0.1 
SM(36:1) 4.8 ± 1.2 5.1 ± 1.6 5.0 ± 1.3 5.4 ± 1.7 5.2 ± 0.6 5.2 ± 0.7 
SM(36:0) 14.4 ± 2.2 17.3 ± 2.9* 12.5 ± 4.1 14.5 ± 3 15.8 ± 3.8 16.2 ± 3.2 
SM(40:7) 1.2 ± 0.4 1.2 ± 0.5 1.2 ± 0.4 1.2 ± 0.4 2.3 ± 0.4 2.6 ± 0.2* 
Table 4. Treatment with IL-1β alters phospholipid profiles in tendon-derived cells. Cells were 
cultured and treated with medium or medium containing 10 ng/mL of IL-1β for 24 hrs. Phospholipids 
were extracted from cell pellets and analyzed by LC-MS/MS. Data is presented as relative abundance 
(area-%, mean ± SD ) of phospholipid species within phospholipid classes. Phospholipids altered in 
the same direction in the three tendon groups are shown in grey. Statistical significance was calculated 
using paired t-test (*P < 0.05 toward Ctrl). 
  47 
 
Figure 4. Effect of mPGES-1 or COX inhibitors on phospholipid profiles in tendon-derived cells. 
Cells were cultured and treated with medium or medium containing 10 ng/mL of IL-1β in presence or 
absence of 10 µM of naproxen, NS-398, or CIII for 24 hrs. Phospholipids were extracted from cell 
pellets and analyzed by LC-MS/MS. Data is presented as relative abundance (area-%) of phospholipid 
species within phospholipid classes. The bars show mean values. Statistical significance was 
calculated using repeated measures ANOVA followed by paired t-test with Bonferroni correction (*P 
< 0.05 towards IL-1β). 
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4.2 INHIBITION OF MPGES-1 IN CANCER 
We have studied the difference in protein and lipid profiles upon inhibition of mPGES-1 or 
COX-2 in cancer cells in vitro (Paper II). CIII reduced PGE2 production and increased PGF2α 
and TXB2 formation while NS-398 reduced the production of all three prostanoids. Our 
proteomics analysis suggested changes in individual proteins that we used to translate into 
cellular functions. The pathway analysis predicted increased cell death with CIII and decreased 
cell death with NS-398. Our lipidomics data supported this effect, where CIII increased two 
sphingolipids (sphinganine and dihydroceramide-C16:0) that are implicated in apoptosis. We 
tested our hypothesis on cell death in a live cell monitoring system but there was no difference 
in cell death in general or apoptosis in specific between the two inhibitors. We then investigated 
the effect on cell proliferation and if the inhibitors would alter the cytotoxicity of cytostatic 
drugs. Our results showed that CIII decreased the proliferation and potentiated the effect of 
cisplatin, etoposide, and vincristine, resulting in enhanced anti-proliferative effect and 
increased cell death.  
We show that inhibition of mPGES-1 reduced tumor growth in two preclinical models of 
neuroblastoma (Paper III). The xenograft model represents injection of SK-N-AS cells, which 
are derived from human high-risk neuroblastoma, into the flank of mice with deficient immune 
system. The transgenic model spontaneously develops tumors that resembles human high-risk 
neuroblastoma. The expression of mPGES-1 is exclusive for stromal cells (fibroblasts, positive 
for platelet-derived growth factor receptor β) in both the xenograft and the transgenic model. 
Daily treatment with CIII (50-100 mg/kg) slowed down the growth of established tumors in 
the xenograft model. This yielded 40% smaller tumors (weight) after nine days of treatment. 
Early treatment with CIII (CIII-ET), i.e. receiving CIII at the day of inoculation with cancer 
cells, did not decrease the tumor weight further. Daily treatment with CIII (50 mg/kg) for ten 
days resulted in 50% smaller tumors (weight) in the transgenic model. Moreover, we showed 
that treated transgenic mice had a shift in macrophage polarization towards anti-tumor M1 
phenotype in the tumors. We also observed decreased tumor angiogenesis and decreased 
infiltration of cancer-associated fibroblasts with CIII treatment in the transgenic model. 
The PGE2 concentration was not reduced in the treated tumors from the xenograft mice, 
sacrificed 24 hrs after the last injection of CIII (mean ± SD pmol/mg extracted tumor; Ctrl: 
0.021 ± 0.019, n=13; CIII-ET: 0.026 ± 0.029, n=8; and CIII: 0.024 ± 0.018, n=11). We 
therefore aimed to investigate the presence of CIII in tumor and plasma. An LC-MS/MS 
method was established and the extraction performance was evaluated based on extraction 
efficiency and matrix effect in mouse plasma. Our method enabled us to quantify CIII and 
PGE2 simultaneously. We performed a kinetics experiment where xenograft mice were 
sacrificed 2, 4, and 6 hrs post-injection of CIII (50 mg/kg i.p.). The concentration of CIII was 
highest at 2 hrs post-injection in both plasma and tumors. This coincide with an 80% reduction 
in PGE2 concentration in the tumor. Other prostanoids were not detected in tumor tissues. We 
also quantified CIII and prostanoids in brains and spleen from the same animals (Figure 5 and 
Figure 6). CIII followed the same profile in the brain as in plasma and tumors, whereas CIII 
seemed to accumulate in the spleen. PGE2 or other prostanoids were mainly unaffected in 
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brains or spleens following this single injection. This experiment confirmed distribution of CIII 
with decreased PGE2 concentration in the tumors at 2 hrs post-injection.  
 
 
Figure 5. Quantification of CIII and PGE2 in plasma, tumor, brain, and spleen from neuroblastoma 
tumor-bearing xenograft mice. Animals were sacrificed 2, 4, or 6 hrs post-injection of CIII (50 mg/kg, 
i.p.). Tissues were extracted and analytes were quantified by LC-MS/MS. A, Data is presented as 
mean ± SEM, n=5-6 per time-point. B, The bars show median values. Statistical significance was 
calculated using Mann-Whitney U test (*P < 0.05). 
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Figure 6. Quantification of prostanoids in brain and spleen from neuroblastoma tumor-bearing 
xenograft mice. Animals were sacrificed 2, 4, or 6 hrs post-injection of CIII (50 mg/kg, i.p.). Tissues 
were extracted and prostanoids were quantified by LC-MS/MS. The bars show median values. 
Statistical significance was calculated using Mann-Whitney U test (*P < 0.05). 
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4.3 CHARACTERIZATION OF NEW MPGES-1 INHIBITORS 
We have demonstrated efficacy of five new mPGES-1 inhibitors in multiple models in vitro, 
in vivo, and ex vivo (Paper IV). The compounds 934, 117, 118, 322, and 323 selectively 
inhibited mPGES-1 in an activity assay against recombinant human and rat mPGES-1. The 
compounds reduced PGE2 production in A549 cells, human whole blood, and in an air pouch 
model in mice. In a paw edema model in rats, the compounds decreased swelling already at 1 
mg/kg. Lastly, the compounds 934 and 118 reduced norepinephrine induced vasoconstriction 
in human small arteries. 
The whole blood assay was developed to screen for changes in multiple eicosanoids. Each 
eicosanoid and corresponding deuterated variant were individually optimized for in the LC-
MS/MS analysis. A dilution curve containing 6-keto PGF1α-d4, PGE2-d4, PGD2-d4, PGF2α-d4, 
TXB2-d4, 15d-PGJ2-d4, LTB4-d4, LTC4-d5, LTD4-d5, 5-HETE-d8, 12-HETE-d8, 15-HETE-
d8, and undeuterated variants of 13-HODE, RvD1, RvD2, 17-hydroxy DHA, and protectin DX 
was spiked into 100 µL plasma at different stages throughout the extraction. A dilution curve 
was spiked in water at the same step. The dilution curve ranged from 0.006-1.5 pmol injected 
on the column in the LC-MS/MS analysis. This enabled us to investigate the lower LOQ, 
recovery efficacy, and matrix effect for each eicosanoid. The lower LOQ injected on column 
was considered as great (0.02-0.05 pmol), good (0.1-0.2 pmol), or poor (0.4-1.5 pmol). 
Eicosanoids with great LOQ were PGE2, PGF2α, TXB2, RvD1, RvD2, LTB4, protectin DX, and 
13-HODE; good LOQ were 6-keto PGF1α, PGD2, 5-HETE, 15-HETE, and LTD4; poor LOQ 
were 15d-PGJ2, 12-HETE, 17-hydroxy DHA, and LTC4. The extraction recovery rates were 
33-125%. The response in plasma compared to 20% MeCN were 52-116% (due to matrix 
effects). The estimated lower LOQ in 100 µL plasma was around 1000 pg/mL for the best 
performing eicosanoids including PGE2, TXB2, PGF2α, RvD1, RvD2, and protectin DX. We 
conclude that the method gave similar quantitative performance in plasma for many 
eicosanoids. 
LPS increased PGE2 and TXB2 production in human whole blood (Figure 7). All other 
eicosanoids were below detection limit. We chose 10 µg/mL of LPS as our final concentration. 
The prostanoid production was blocked with diclofenac (10 µM). High concentration of DMSO 
(0.1%) slightly decreased PGE2 production. The intra-assay coefficient of variation (CV, n = 
20 technical replicates) was 12% and 11% for PGE2 and TXB2, respectively. The inter-assay 
CV for control material (CV, mean, n = 3 donors) was 20% for PGE2 and 30% for TXB2. This 
was performed on blood that was drawn, incubated, extracted, and analyzed at separate 
occasions. The suppression in signal due to matrix effects and/or recovery efficiency varied 
between donors and experiments, ranging from 10-70% suppression compared to signal in 
extracted blank (mean ± SD, n=6 donors, PGE2: 45±25%, TXB2: 40±20%). This assay was 
used to determine IC50 values of the new mPGES-1 inhibitors in human whole blood. 
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Figure 7. Set up of human whole blood assay. Heparin blood was incubated for 24 hrs with 10 µg/mL 
of LPS (if not stated otherwise) to induce PGE2 and TXB2 production, as measured by LC-MS/MS. A, 
LPS induced PGE2 and TXB2 production. B, Diclofenac (10 µM) blocked induced prostanoid 
production. B and C, High DMSO concentration affected PGE2 production. D, Inter-assay CV was 
12% and 11% for PGE2 and TXB2, respectively. DICLO, diclofenac. 
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5 DISCUSSION AND FUTURE PERSPECTIVES 
Preclinical work has demonstrated that inhibition of mPGES-1 has many clinical possibilities. 
Then again, the drug development of mPGES-1 inhibitors have been halted due to absence of 
potent inhibitors lacking interspecies differences, fear of severe adverse effects when targeting 
the COX pathway, and no clear strategy which diseases to primarily target. This thesis aimed 
to address some of these issues, and this is reflected in the diversity of the papers included. 
Inhibition of mPGES-1 in inflammation: prostacyclin and cardiovascular safety 
Tendinopathy belongs to the diseases of musculoskeletal soft tissues, which are a major cause 
of pain and impaired physical function (350). Inflammation was long considered to not play a 
role in tendinopathy, mainly because there was no infiltration of neutrophils or macrophages 
at the site of injury. This was attributed by the relatively late presentation to the clinics, and it 
is now evident that inflammatory processes contribute to the onset and the progression of 
tendon disease (351, 352). However, the precise mechanisms are poorly understood. 
Based on previous literature that describes prostacyclin as a mediator of pain and edema (37, 
98-102), our initial results suggested that prostacyclin contributes to these responses in tendon 
disease (Paper I). We therefore hypothesized that the expression of PTGIS would be lower in 
patients that had resolved pain post-surgical treatment compared to those that were still in pain. 
Since our results showed the opposite, we rejected the hypothesis that PTGIS expression (= 
prostacyclin production) correlated with pain in tendon disease. Instead, based on prostacyclin 
as a vasodilator and anti-platelet activator, we speculate that prostacyclin may be a defensive 
response to enable vascularization and limit thrombosis at site of tendon injury. For example, 
PGIS and not mPGES-1 is increased upon hypoxia during inflammation in vascular smooth 
muscle cells and endothelial cells as a potential protective response (353). We acknowledge 
that there is a limitation in measuring the mRNA and not the actual PGIS protein abundance or 
prostacyclin concentration in this setting. However, these tendon biopsies were very small 
(especially from patients that had resolved pain) and only qPCR analysis was estimated 
sensitive enough. 
NSAIDs use is heavily debated due to the many adverse effects and these drugs are regarded 
as “resolution toxic” (23), given the inhibition of SPM biosynthesis required in the resolution 
of inflammation. NSAIDs are specifically controversial in tendon disease as they affect tendon 
mechanical properties negatively and impair tendon healing (354, 355). This could be due to 
inhibition of SPMs and/or potentially protective prostacyclin production. Moreover, diseased 
tendon tissue expressed mPGES-1, although the functional role of PGE2 in tendon biology is 
inconclusive. Studies have showed increased concentration of PGE2 in connective tissue after 
mechanical load exercise in healthy humans (356) and in in vitro models of fibroblast cultures 
(357, 358). The use of aspirin or indomethacin blocked baseline and induced PGE2 production, 
which decreased the otherwise increase in blood flow in connective tissue of human subjects 
following exercise (356). In the same study, celecoxib blocked only the induced production of 
PGE2. This suggests that an initial burst of PGE2 is important to initiate inflammation 
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(increased blood flow) and subsequent resolution. Repeated injection of PGE2 was found to 
improve mechanical properties of tendons in rats (359). However, similar injections are 
reported to cause degenerative processes in rabbits (360). Given the massive amount of 
literature that describe COX/mPGES-1/PGE2 as a key pathway in preclinical models of 
inflammation or in patients with rheumatic diseases (5, 53-56, 98, 238, 240-243, 295, 296, 310, 
361-363), we speculate that inflammation (edema and pain) in tendon disease is at least partly 
driven by the excessive production of PGE2. Inhibition of mPGES-1 would then be superior to 
NSAIDs, as this reduces the production of seemingly detrimental PGE2, increases the 
production of potentially protective prostacyclin, and spare the inhibition of COX for 
generation of SPMs.  
If mPGES-1 inhibitor would be analgesic in tendon disease is difficult to predict, mainly 
because pain can come in many flavors. While mPGES-1 deficient mice display less pain in 
some models but not all (237, 238, 240, 263), Sugita et al. reported that simultaneous targeting 
of prostacyclin and PGE2 signaling or production was needed for analgesic effect in pain 
models in mice, since celecoxib exhibited this effect while mPGES-1 inhibition or IP receptor 
antagonist alone did not (364). Inhibitors of mPGES-1 typically demonstrate analgesic effect 
in preclinical models of inflammatory pain (295, 296, 362, 363). The significant difference in 
disease characteristics between human tendinopathy and experimental tendinopathy in animal 
models (365) makes it difficult to test mPGES-1 inhibition in a preclinical and functional 
setting in tendon disease. 
Inhibition of mPGES-1 is likely to be as efficient as inhibition of COX in terms of reducing 
PGE2 production, where the selective inhibition of mPGES-1 will spare the production of other 
prostanoids. As described earlier, this is important from the cardiovascular point of view. We 
showed that diseased tendon-derived cells treated with CIII produced more prostacyclin, in line 
with that CIII increased prostacyclin formation in mouse peritoneal macrophages (262). 
Increased prostacyclin formation has been reported in mPGES-1 deficient mice as measured in 
urine (60, 61, 205, 366), and multiple studies support that genetic deletion of mPGES-1 is safer 
compared to deletion or inhibition of COX-2 in terms of hypertension and evoked thrombosis 
(205, 239, 367). The systemic shift from PGE2 to prostacyclin, as measured by urinary PGEM 
and PGIM concentrations, has been confirmed with an mPGES-1 inhibitor in man (368). 
However, recent work suggest that urinary PGIM could be derived from kidney prostacyclin 
without contribution from systemic prostacyclin production (369), which then places a question 
mark on the urinary PGIM levels as a reflection of endothelial derived prostacyclin 
biosynthesis in the cardiovascular system. On the other hand, it was recently demonstrated in 
an ex vivo model of human vascular tone that CIII decreased norepinephrine-induced 
vasoconstriction via prostacyclin formation (370), and we conclude that CIII and our new 
mPGES-1 inhibitors replicated this effect in human vessels (Paper IV). Recent mechanistic 
data in mice support that mPGES-1 drives vascular remodeling, stiffness, and endothelial 
dysfunction in hypertension via oxidative stress (371). Inhibition of mPGES-1 is therefore 
suggested cardioprotective, where the potential shunting towards prostacyclin in vivo needs to 
be further evaluated. 
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It would be interesting to investigate the clinical significance of an mPGES-1 inhibitor in 
tendon disease, especially since NSAIDs are associated with decreased tendon healing. As 
mentioned above, animal models do not fully replicate human tendon disease. Our in vitro 
experiments could be expanded to investigate the effect of mPGES-1 or COX inhibition on for 
example markers of fibroblast activation, in line with recent work showing that two species of 
SPMs altered inflammatory signatures in stromal cells from Achilles tendons (372).  
For the cardiovascular safety, we plan to investigate the protective mechanisms in human 
arteries further. Apart from demonstrating actual increase in prostacyclin formation upon 
mPGES-1 inhibition in this setting, it is important to demonstrate that the use of an IP receptor 
antagonist renders the effect on vasoconstriction. It would therefore be essential to investigate 
expression patterns of IP and EP receptors in these vessels. Additionally, experiments where 
vessels are treated with different concentration (or ratios) of PGE2 and prostacyclin analogs are 
suggested to elucidate the direct actions of these PGs in different types of vessels. 
Inhibition of mPGES-1 as adjuvant therapy in cancer 
Multiple studies have demonstrated that genetic deletion of mPGES-1 results in slower 
growing tumors in vivo, but few studies have been reported using pharmacological inhibition 
of mPGES-1 in cancer models. Our proteomic and lipidomic data suggested that mPGES-1 
inhibitor CIII promoted a pro-cell death state in vitro (Paper II). Although CIII alone did not 
induce apoptosis in specific or cell death in general in A549 cells, CIII decreased proliferation 
rate and increased the cytotoxicity of cytostatic drugs. In other words, CIII potentiated cell 
death at 10 µM of cisplatin, 10 µM of etoposide, or 0.01 µM of vincristine. This means that a 
lower dose of cytostatic drugs could be used to achieve the same efficacy in cell death, and this 
may have important implications on mPGES-1 inhibitors as adjuvant therapy in cancer. 
Decreasing the cytostatic drug dose without compromising its efficacy translate into potentially 
less adverse effects from cancer therapy in patients. 
Daily treatment with CIII reduced neuroblastoma tumor growth in vivo (Paper III). Our in 
vivo results fit well into the literature on mPGES-1 and cancer. Especially the reduction in 
tumor angiogenesis has been demonstrated in mPGES-1 KO mice (250-253) and in mice 
treated with an mPGES-1 inhibitor (302). The shift in macrophage polarization from M2 to M1 
in the tumor microenvironment has been reported in a transgenic breast cancer model using 
mice lacking mPGES-1 (256). Despite that our in vivo study focused on neuroblastoma, we 
believe that mPGES-1 inhibition is a beneficial therapeutic strategy for multiple cancer. This 
is supported by the presence of COX/mPGES-1/PGE2 pathway in multiple forms of cancer 
(41-48) and the anti-cancer effects observed in mice lacking mPGES-1 (48, 52, 103, 250-256). 
However, NSAIDs or mPGES-1 inhibitors alone are not resulting in complete halt in tumor 
growth. We acknowledge that mPGES-1 inhibitors are not intended as single treatment, much 
like the current use of NSAIDs treatment of cancer in clinical practice. Instead, the selective 
reduction in oncogenic and immunoregulatory PGE2 is likely to replicate observations with 
COX inhibition or deletion in cancer models and at the same time spare the many adverse 
effects (25, 342). 
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Resistance to celecoxib has been reported for colon adenomas patients, and this correlated with 
low expression of tumor 15-PGDH (373). The authors demonstrated that tumor-bearing 15-
PGDH KO mice were resistant to celecoxib treatment. 15-PGDH expression is repressed in 
some of the most common types of cancer including colon (374, 375), gastric (376), lung (377), 
and breast (378). Targeted overexpression of 15-PGDH in tumor tissue slowed down tumor 
growth via a shift in macrophage polarization from M2 to M1 and induction of T cell immune 
response in a mice model of colon cancer (379). These studies highlight that both the machinery 
for anabolism and catabolism of PGE2 are important for therapeutic use of NSAIDs and likely 
mPGES-1 inhibitors. The issue with potential resistance to mPGES-1 inhibition when the 
expression of 15-PGDH is low may be circumvented via the potential redirection from PGE2 
production towards PGD2 and 15d-PGJ2 formation in macrophages (236), where 15d-PGJ2 
treatment was recently shown to increase the expression of 15-PGDH in breast cancer cells in 
vitro (380). 
Meta-analysis showed that intake of NSAIDs in cancer pre- or post-diagnosis decreased 
metastasis (381), in line with results from in vivo models using mPGES-1 KO mice (250, 252). 
This suggest that mPGES-1 inhibitors may not only control primary tumor growth but also 
metastasis formation. NSAIDs potentiate chemotherapy in vitro (382) and immunotherapy in 
vivo (52, 383). Celecoxib can enhance the response to conventional treatment or even overcome 
treatment resistance in cancer (384-388). Specifically, celecoxib enhanced potency of 
chemotherapy, such as vincristine and doxorubicin, in neuroblastoma in vitro and in vivo (389). 
Recent data using RNAi towards mPGES-1 or inhibition of EP4 signaling sensitized 
oxaliplatin-resistant HT29 cells to oxaliplatin (390). Knock-down or inhibition of mPGES-1 
with MF63 increased the efficacy of EGFR inhibitor erlotinib in prostate cancer cells in vitro 
and in vivo (391). Kim et al. recently showed that high expression of mPGES-1 in stage III 
melanoma tissue correlated with low infiltration of CD8pos T cells and shorter survival (392). 
They demonstrated that deletion of mPGES-1 in a syngeneic melanoma mouse model 
increased the infiltration of CD8pos T cells, slowed down tumor growth, and enhanced the 
efficacy of anti-PD1 treatment. Inhibition of mPGES-1 is therefore likely to have anti-
carcinogenic effects via several mechanisms including decreased cancer cell proliferation, 
decreased tumor angiogenesis, promotion of anti-cancer macrophage polarization, re-
activation of cytotoxic T cells, and increased effect of conventional therapy. 
The next step is to further investigate the synergistic or additive effects of mPGES-1 inhibition 
with cytostatic drugs, targeted therapy, or immunotherapy in vitro and in vivo. These 
experiments can be performed with the new mPGES-1 inhibitors and additional COX inhibitors 
in parallel, in order to both validate the effect of CIII and to distinguish therapeutic 
opportunities between targeting mPGES-1 over COX enzymes in cancer. 
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Translating lipidomics data  
Multiple differences in phospholipids were found upon IL-1β treatment and/or inhibition of 
mPGES-1 or COX enzymes (Paper I and Paper II). Despite studies on the associations of 
distinct phospholipid species with for example lung cancer tissue compared to healthy tissue 
(393-395) or altered membrane phospholipids in macrophages based on polarization phenotype 
in vitro (396), lipidomics is an underdeveloped field of research compared to other omics. The 
amount of publications on PubMed (www.ncbi.nlm.nih.gov, accessed on 2019-03-18) 
containing the word genomics, proteomics, metabolomics, or lipidomics during last year 
(2018) were 20922, 7415, 4307, and 574, respectively. Lipidomics is most often viewed as a 
subgroup to metabolomics, and lipids as biomolecules have been extensively studied for a long 
time with an ongoing effort in standardizing the analysis and the reporting of lipidomics data 
(Lipid Maps, www.lipidmaps.com). However, there is a lack of knowledge regarding the 
biological significance of distinct lipid species and lipid perturbation. This is a key problem, 
nicely described by Anthony D. Postle: "One conceptual problem about phospholipids is that, 
with a few notable exceptions, it is very difficult to claim a unique function for any individual 
molecular species, defined by a combination of headgroup and fatty acyl chains esterified the 
sn-1 and sn-2 positions of the glycerol backbone" (397). This is in contrast to assigning 
functions to a specific gene or protein. Generating relevant lipidomics data is demanding but it 
is not the bottleneck. Instrumentation, methods, and appropriate samples are in place. The 
challenge is to interpret and translate the phospholipid data into biological relevance. 
The ambition would be to create a library of phospholipids and their relative changes in 
different cellular responses. A starting point is to use cell lines (e.g. A549 cells) to first 
characterize the basal lipidome and perturbations induced by different standard stimuli, such 
as LPS, cytokines, staurosporine, or rapamycin. It would then be possible to assign a stimulus 
(or cell state) to a certain phospholipid profile. This would generate a library of fingerprints. A 
new stimulus, such as an inhibitor, can then be added to the cells and any change in 
phospholipid profile can be compared to the library to see if the response is towards any of the 
standard stimuli. The library can be expanded with multiple cell lines and complemented with 
data from fatty acid analysis, secreted factors (prostanoids, cytokines), and proteomics. Even 
if it would still be difficult to determine if changes in specific phospholipids are a mere 
consequence of the cell state or actual contribution to the cell state, this knowledge would 
increase the biological association of phospholipid species. 
Development of mPGES-1 inhibitors 
Several mPGES-1 inhibitors have been reported in recent years, including many patents (398). 
Despite the many advances, there is a lack of selective mPGES-1 inhibitors with high potency 
and good bioavailability in rats or mice to facilitate preclinical studies.  
The main breakthrough since 2015 was the publication of the first Phase I trial on an mPGES-
1 inhibitor (368). As mentioned earlier, the Eli Lilly compound LY3023703 decreased urinary 
PGEM and increased urinary PGIM and 11-dehydro TXB2, and there was no increase in TXB2 
formation in serum. LY3023703 dose-dependently inhibited PGE2 production in human whole 
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blood ex vivo. Regardless of the promising results, one subject developed drug-induced liver 
injury as determined by elevated levels of serum alanine aminotransferase levels upon taking 
30 mg/day of LY3023703 for 28 days. A follow-up compound, LY3031207, was tested in a 
Phase I trial but the study was terminated when several subjects developed drug-induced liver 
injury (399). The authors concluded that this is unlikely an mPGES-1/PGE2 driven adverse 
effect but rather caused by the conversion of the inhibitors into toxic metabolite(s) (400). 
Eli Lilly disclosed a SAR study in 2016 wherein they highlighted two compounds for clinical 
investigations (401). Compound 8 inhibited recombinant mPGES-1 with an IC50 of 1 nM and 
PGE2 production in human whole blood with an IC50 of 12 nM, but it displayed poor solubility. 
The follow-up compound 26 was less potent in recombinant assay and human whole blood but 
showed good pharmacokinetics profile in dogs. Eli Lilly described additional inhibitors 
including compound 14 (402) and compound 16 (403). Both were reported as highly selective 
and potent, where compound 16 displayed an IC50 of 1 nM in recombinant assay and 6 nM in 
whole blood assay. In pharmacokinetics studies in rats and dogs, compound 16 was found in 
plasma above the IC80 value measured in human whole blood assay (24 nM) for up to 24 hrs 
following a single oral dose. 
Sugita et al. reported that Compound A blocked PGE2 production with an IC50 of 13 nM in 
A549 cells, and that this caused an increase in other prostanoids (361). Compound A decreased 
PGE2 biosynthesis in rat peritoneal macrophages (IC50 of 1.9 µM) that coincide with an 
increase in PGF2α formation. Moreover, Compound A was anti-pyretic in LPS-induced pyrexia 
model and anti-inflammatory in adjuvant-induced arthritis models in rats (30 mg/kg oral 
gavage, p.o.). Glenmark Pharmaceutical Ltd. recently disclosed two SAR studies. Inhibitor 17d 
displayed potency in human whole blood and showed analgesic effect in guinea pigs (362). 
The company presented several highly selective mPGES-1 inhibitors with good potency 
against recombinant enzyme (IC50 down to 4 nM) but the inhibitors displayed loss in potency 
in A549 cells (IC50 >250 nM, at 2% serum) (363). The best performing inhibitor was 
Compound 9, which displayed poor performance in vivo.  
A few new dual mPGES-1 and 5-LO inhibitors have been disclosed since 2015. Svouraki et 
al. presented a SAR study on natural-derived compounds with low potency towards 
recombinant enzymes (IC50 values of 1-5 µM), although the most potent compound slightly 
decreased inflammatory cell infiltration in zymosan induced peritonitis (10 mg/kg i.p.) (404). 
Moreover, Compound 47 caused a shift in eicosanoid production from prostanoids and 
leukotrienes to SPMs in human macrophages (405). This inhibitor displayed activity in vivo 
with decreased production of PGE2 in peritonitis and air pouch models in mice.  
Multiple computational studies to facilitate the development of mPGES-1 inhibitors have 
been performed recently. For example, molecular docking was used to identify lead structures 
from natural compounds (406) and to develop Compound 8n that inhibited PGE2 production 
in RAW 264.7 cells with IC50 of 4.5 nM (407). Gupta et al. performed comprehensive 
molecular docking and SAR studies with 127 compounds extracted from the literature up 
until 2015 (408, 409), highlighting amino acids in human mPGES-1 that are shared between 
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inhibitors. Zhao et al. used virtual screening to identify new compounds that they tested 
against recombinant mPGES-1 with IC50 of >250 nM (410). Di Micco et al. used molecular 
docking and SAR studies to identify new scaffolds that inhibited recombinant human 
mPGES-1 down to IC50 of 180 nM (411). Last year, Ding et al. reported the compound 4b 
with potency in both human and murine models (412). Compound 4b inhibited recombinant 
mPGES-1 with IC50 of 33 nM (human) and 157 nM (mouse), and this inhibitor was reported 
to decrease PGE2 production in an air pouch model in mice (>5 mg/kg p.o). High dose (up to 
1000 mg/kg p.o.) did not cause ulcers whereas celecoxib (50 mg/kg p.o.) did. These studies 
expand knowledge of existing inhibitors and speed up the development of future inhibitors.  
Our newly characterized mPGES-1 inhibitors are highly selective and potent in recombinant 
assay and intact A549 cell assay. However, the inhibitors showed loss in potency in human 
whole blood. This is similar to many other mPGES-1 inhibitors (Table 2). Our new inhibitors 
showed good efficacy in in vivo models, which is similar to Compound A and Compound 4n 
(Table 4). Of significance, our inhibitors reduced paw swelling already at 1 mg/kg p.o.. 
Collectively, five additional mPGES-1 inhibitors are described that opens up for opportunities 
to study mPGES-1 inhibition in inflammation and cancer in preclinical settings.  
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Inhibitor (year) Species 
activity 
Recombinant 
mPGES-1 (IC50) 
Human whole 
blood (IC50) 
Results from in 
vivo models 
Ref. 
CIII (2013) Human, 
murine 
0.09 µM (human), 
0.9 µM (rat) 
~10 µM Decreased PGE2 
and cells (air pouch, 
rat) 
(262) 
LY3023703 
(2016) 
Human Not disclosed “17-fold more 
potent than 
celecoxib” 
Analgesic (guinea 
pig, not disclosed) 
(368) 
Compound 8 
(2016) 
Human 0.001 µM (human), 
34 µM (rat) 
0.012 µM Bioavailability of 
37% (dog) 
(401) 
Compound 26 
(2016) 
Human 0.241 µM (human), 
>1000 µM (rat) 
0.744 µM Bioavailability of 
60% (dog) 
Compound A 
(2016) 
Human, 
murine 
0.013 µM (human), 
0.002 µM (rat)# 
Not tested Anti-pyretic, anti-
inflammatory (rat) 
(361) 
17d (2016) Human 0.008 µM (human), 
0.011 µM (guinea 
pig) 
0.250 µM Analgesic at >30 
mg/kg (guinea pig) 
(362) 
Compound 9 
(2017) 
Human 0.057 µM (human) Not tested. Analgesic at 200 
mg/kg (guinea pig) 
Bioavailability of 
33% (rat) 
(363) 
16 (2017) Human 0.0001 µM 0.006 µM Bioavailability of 
60% (dog) 
(403) 
Compound 4b 
(2018) 
Human, 
murine 
0.033 µM (human), 
0.157 µM (mouse) 
Not tested. Decreased PGE2 (air 
pouch, mouse), No 
GI toxicity (mouse) 
(412) 
934, 117, 118, 
322, and 323 
(2019) 
Human, 
murine 
0.010-0.029 µM 
(human), 
0-067-0.250 µM 
(mouse) 
3.3-8.7 µM Decreased PGE2 (air 
pouch, mouse), 
Reduced paw 
swelling (rat), 
Bioavailability of 10-
46% (rat) 
Paper IV 
Table 4. Selective mPGES-1 inhibitors, as of March 2019. This list is an extension of Table 2. CIII 
is included as reference for best performing inhibitor that lacks interspecies differences, as of before 
this thesis was conducted. #Intact cell assay of human A549 cells or mouse peritoneal macrophages. 
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6 CONCLUSION 
The key inflammatory enzyme mPGES-1 has been an anticipated therapeutic target ever since 
characterized 20 years ago. A few clinical trials have been performed but no mPGES-1 
inhibitor has reached clinical practice. This doctoral thesis provides increased knowledge of 
mPGES-1 and its inhibition in models of inflammation and cancer. The results are important 
pieces in the large effort of bringing mPGES-1 inhibitors into clinical practice. This thesis 
showed that inhibition of mPGES-1 decreased PGE2 biosynthesis and that this: 
- increased the formation of potentially protective prostacyclin in an in vitro model of 
tendon disease, 
- resulted in decreased proliferation and increased cytostatic-induced cell death in lung 
cancer cells in vitro, 
- decreased tumor growth in two preclinical models of neuroblastoma in vivo, and 
- reduced paw swelling in a preclinical model of edema in vivo and made human 
vessels less prone to contract ex vivo. 
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